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ABSTRACT 
AURELIE M. GRESSET: Mechanism of phosphorylation-induced activation of 
phospholipase C-γ isozymes 
(Under the direction of John Sondek) 
 
Phospholipase C (PLC) isozymes regulate numerous cellular events including 
fertilization, proliferation, differentiation, and chemotaxis.   PLCs hydrolyze 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) into the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which activate protein kinase 
C (PKC) and liberate intracellular calcium, respectively.  Numerous transmembrane 
receptor (RTKs) and cytosolic tyrosine kinases recruit and phosphorylate PLC-γ 
isozymes (γ1 and γ2) to enhance their phospholipase activities, leading to ventricular 
contractility, angiogenesis, and cell motility among other processes.  The molecular 
details linking phosphorylation and activation of PLC-γ isozymes remain poorly 
understood. 
The majority of PLC enzymes are auto-inhibited by a highly disordered and 
electronegative linker inserted between the two halves (X and Y box) of the catalytic 
TIM barrel.  Recent data support a model of interfacial activation for most PLCs whereby 
the X/Y-linker is removed from the active site by electrostatic repulsion with lipid 
membranes, thus coupling localization and orientation of PLCs at substrate membranes 
with their activation.  However, PLC-γ isozymes are structurally unique in having 
acquired several modular domains – a split PH domain, a tandem SH2 domain, and an 
SH3 domain – within the X/Y-linker. 
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In this study, we investigate the roles of the highly elaborated X/Y-linker in 
regulating the phospholipase activity of PLC-γ isozymes.  We identified the C-terminal 
SH2 (cSH2) domain within the X/Y-linker as the critical structural determinant in 
regulating the auto-inhibition of PLC-γ isozymes and demonstrate how tyrosine 
phosphorylation leads to phospholipase activity.  Deletion of the cSH2 domain fully 
recapitulates the robust, constitutive phospholipase activity of PLC-γ isozymes lacking 
the entire X/Y-linker.  Moreover, phosphorylation of PLC-γ1 at Tyr783 within the X/Y-
linker promotes high affinity interactions with the cSH2 domain required for 
phospholipase activation.  These interactions induce large conformational rearrangements 
that facilitate substrate access and subsequent hydrolysis.  Consequently, the X/Y-linker 
distinctly regulates several aspects of PLC-γ activity: i) it auto-inhibits basal 
phospholipase activity of PLC-γ isozymes, ii) it is required for recruitment of PLC-γ 
isozymes to RTKs, and iii) phosphorylation of the X/Y-linker relieves this auto-
inhibition.  Overall, PLC-γ isozymes elaborate upon a general mechanism of auto-
inhibition by the X/Y-linker found in most PLCs to couple tyrosine phosphorylation with 
phospholipase activation. 
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This work is dedicated to my grandfather, Marc Ycard, who has inspired me to reach the 
best of my abilities and who I miss dearly. 
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CHAPTER 1: INTRODUCTION 
Part I: Cell signaling 
The ability of cells to perceive, respond, and adapt to their microenvironment is 
essential for cellular homeostasis.  Diverse stimuli, including hormones, 
neurotransmitters, cytokines, and growth factors, bind and activate cell-surface receptors 
to elicit acute cellular responses, as well as to promotes changes in gene synthesis.  
Chains of interacting proteins, known as signaling pathways, are utilized by cells to 
transmit signals from the extracellular matrix to the nucleus.  In addition to transmitting 
the signal, signaling pathways also amplify the incoming signal and modulate the kinetics 
of the cellular response.  An essential step in signal amplification is the production of 
second messengers that act as transducing molecules to couple cell-surface receptors to 
intracellular pathways.  Key second messengers are inositol-1,4,5-trisphosphate 
(Ins(1,4,5)P3) and diacylglycerol (DAG) produced by phospholipase C (PLC)-mediated 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2).  
History of calcium signaling and the role of inositol phosphates 
In 1953, Hokin and Hokin proposed a “PI-effect” in which stimulation of 
pancreas slices by cholinergic drugs led to increased incorporation of 32P into 
phosphatidic acid and phosphatidylinositol (PI), suggesting for the first time that 
phospholipid turnover was directly related to hormone-stimulated receptors (1).  In 1964, 
Thompson and Dawson isolated a PtdIns(4,5)P2-specific PLC from brain tissue (2).  
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Inositol lipid metabolism was first placed downstream of receptor activation in 1969 by 
Durell and collegues (3).  In 1975, Robert Michell associated the “PI effect” with an 
increase in intracellular Ca2+ (4).  Four years later, Berridge and Fain validated that 
inositol synthesis through phospholipid hydrolysis was directly linked to Ca2+ 
mobilization, and first suggested a functional significance for Ins(1,4,5)P3 (5).  At the 
same time, Nishizuka’s group discovered protein kinase C (PKC) and proposed that PKC 
was regulated in vivo by DAG (6).  PtdIns(4,5)P2 was shown to be the substrate of 
receptor-stimulated PLC enzymes by Michell and coworkers in 1981 (7).  In 1982, 
Berridge realized that both Ins(1,4,5)P3 and DAG came from PLC-mediated 
PtdIns(4,5)P2 hydrolysis, indicating that both Ins(1,4,5)P3 and DAG are second 
messengers derived from the same reaction (8).  Streb et al. established that Ins(1,4,5) 
directly mobilizes Ca2+ from intracellular stores within the endoplasmic reticulum (ER) 
(9).  The Ins(1,4,5)P3 receptor was subsequently identified and cloned shortly thereafter 
(10).  These pioneering studies layed the groundwork for research groups to investigate 
intricate signaling pathways integrated through PLC-mediated phospholipid metabolism 
(Figure 1). 
PtdIns(4,5)P2 as a second messenger 
After getting a lot of attention in the 1970s for being the substrate of the PLC-
driven reaction, the signaling role of PtdIns(4,5)P2 itself was recognized in the 1990s (11, 
12).  Twenty five-fold higher than other phospholipids that bind to conserved domains, 
PtdIns(4,5)P2 is the most abundant poly-phosphoinositide in the plasma membrane and 
accounts for 1% of the acidic lipid in the whole cell (13).  Total PtdIns(4,5)P2 
corresponds to 5,000–10,000 molecules per µm2 of plasma membrane and would be 
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equivalent to a 4 - 10 µM solution if dissolved in cytoplasm.  PtdIns(4,5)P2 has three 
phosphate groups, one of which is in a phosphodiester linkage, and a net charge near −4 
at neutral pH (13).  Therefore, any protein with a cluster of four or more basic residues 
would laterally sequester PtdIns(4,5)P2 to facilitate recruitment at the plasma membrane 
(13). 
PtdIns(4,5)P2 serves as a targeting anchor for proteins that catalyze endocytosis 
and exocytosis (14), for small GTPases (15, 16), and for components of the actin 
cytoskeleton (17, 18).  Binding of PtdIns(4,5)P2 is accomplished by a variety of domain 
architectures including PH (pleckstrin homology), ANTH (AP180 N-terminal homology), 
ENTH (epsin N-terminal homology), and FERM domains (19), as well as surface-
exposed basic patches (20). 
PtdIns(4,5)P2 is essential for the operation of certain ion channels and transporters 
in the plasma membrane, as temporary depletion of PtdIns(4,5)P2 by PLC’s signaling 
transiently shuts down these functions (21, 22).  Specifically, PtdIns(4,5)P2 regulates the 
activity of inwardly rectifying K+ (Kir) channels (23), KCNQ channels (24), transient 
receptor potential (TRP) channels (25, 26), and ion transporters such as the Na+-Ca2+ 
exchanger (27). 
PtdIns(4,5)P2 is also the substrate of phosphoinositide 3-kinase (PI3K) to catalyze 
the production of PdtIns(3,4,5)P3, a third second messenger mediated by PtdIns(4,5)P2 
metabolism (28).  Production of PtdIns(3,4,5)P3 elicits numerous responses that affect 
cell growth, cell survival and cell movement (29).  Specific proteins, typically through 
their PH domains are recruited to the site of PI3K activation via interaction with 
PtdIns(3,4,5)P3 (19).  For example, the serine/threonine protein kinase Akt, also known 
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as protein kinase B (PKB) (30) and its activator phosphoinositide-dependent kinase 1 
(PDK1) are recruited at the plasma membrane by PtdIns(3,4,5)P3 (31).  Activated Akt 
promotes cell growth and survival by inhibiting proapoptotic Bcl-2 family members BAD 
and BAX (32-34).  Akt also enables NF-κB-promoted transcription of antiapoptotic and 
prosurvival genes (35, 36).  Phosphorylation of Mdm2 by Akt antagonizes p53-mediated 
apoptosis (37, 38), and Akt negatively regulates forkhead transcription factors (39, 40), 
thereby reducing production of cell death-promoting proteins. 
PtdIns(4,5)P2  and its metabolites function in an array of crucial cellular 
processes.  Therefore, enzymes that control PtdIns(4,5)P2 levels are essential for 
maintaining cellular homeostasis.  This work will specifically focus on the PLC enzymes 
that hydrolyze PtdIns(4,5)P2 into Ins(1,4,5)P3 and DAG. 
Phosphoinositide-specific phospholipase C 
The first PLC enzyme purified to homogeneity from rat liver was PLC-α (41).  
Additional PLC isoforms, δ, β, and γ, were subsequently purified and cloned (42-46).  
PLC-α was removed from the PLC family due to its original mischaracterization as a 
proteolytic fragment of PLC-δ1 (47), and further indications that the PLC-α gene actually 
encoded a protein disulfide isomerase, isozyme Q2, and therefore possess no PLC 
activity (48).  Additional PLC isozymes (-ε, -ζ, -η) were subsequently discovered and 
cloned (49-53), for a total of six mammalian PLC family members.  A seventh family, 
PLC-like (PLC-L) closely related in sequence to PLC-δ isoforms (54-56), has no 
catalytic activity due to the substitution of a strictly conserved histidine essential for 
lipase activity for threonine (57) and thus will not be further discussed. 
Catalytic function and structure of conserved core PLC domains 
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PLC enzymes are calcium-dependent phosphodiesterases that hydrolyze 
PtdIns(4,5)P2 into DAG and Ins(1,4,5)P3 (58) (Figure 1).  The structural topology of PLC 
isozymes consists of the following core domains: an N-terminal PH domain (except in 
PLC-ζ), an array of four EF-hands, a catalytic triose phosphate isomerase (TIM) barrel, 
comprised of two halves (X and Y boxes), and an adjacent C2 domain (59).  Outside 
these core domains, PLC enzymes have evolved additional regulatory domains that 
engender unique regulatory mechanisms (60). 
PH domains have a conserved tertiary structure, composed of a sandwich of seven 
β-strands capped on one end by a C-terminal α-helix and on the other end by three 
variable loops, which diverge in both length and amino acid sequence (61).  Although the 
structural folds of PH domains are conserved, their functions are diverse (61).  The PH 
domains of PLC-δ and PLC-γ isoforms bind PtdIns(4,5)P2 and PtdIns(3,4,5)P3, 
respectively (62-64).  Moreover, the PH domains of PLC-δ1 is highly mobile and 
tethered to the rest of the protein via a flexible linker between the PH domain and the EF 
hands (62) (Figure 4).  In contrast, the PH domain of PLC-β2 mediates protein-protein 
interactions with the small GTPase Rac (66, 67) (Figure 5).  In addition, structures of 
PLC-β isoforms indicate that the PH domain makes direct contacts with the rest of the 
core domains and remains packed against the core protein in the presence of different 
activators (63-65).  These results suggest that the PH domain within PLC isoforms have 
functionally distinct roles (66). 
Typical EF-hands are calcium-binding motifs composed of two helixes (E and F) 
joined by a loop and divided into pairwise lobes (67).  In structures of both PLC-δ1 and 
PLC-β2, the electron density of the loops connecting the secondary elements of the EF 
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hands is incomplete, indicating a high degree of flexibility for this domain (65, 67, 68).  
In addition, neither structure has calcium ions bound, suggesting that the EF-hands of 
most PLCs are degenerate and incapable of binding calcium.  Recent structural data from 
the PLC-β3•Gαq complex highlights a novel function for EF hands (65) (Figure 5).  The 
loop between the third and fourth EF hands contains the structural determinants necessary 
for GAP activity of PLC-β3 (65).  The same loop in the holoenzyme is missing from the 
final refined structure (64), strongly indicating that the presence of Gαq stabilizes this 
loop.  This previously unidentified function indicates that the loops within the EF hands 
contain structural determinants facilitating functions other than calcium binding. 
The C2 domain folds into an eight β-stranded antiparallel sandwich, with three 
loops at one end of the sandwich forming calcium binding sites (68).  Structural 
information from PLC-δ1 and PLC-β2 reveal that both C2 domains are structurally 
identical and are tightly packed against the catalytic TIM barrel, likely to maintain the 
structural integrity of the whole protein (65, 67, 68).  Aside from providing structural 
support, the functional role of the C2 domain in PLC isozymes is divergent.  The C2 
domain of PLC-δ1 binds calcium and allows PLC-δ1 to translocate to the plasma 
membrane (69) (Figure 4).  However, the residues coordinating calcium in PLC-δ1 are 
not conserved throughout all PLC isozymes, suggesting that the function of the C2 
domain diverges among PLC isoforms.  For example, the C2 domain of PLC-β3 mediates 
protein-protein interactions with the GTPase Gαq, as a small effector motif, unique to 
PLC-β isozymes, is “grafted” onto the C-terminal of the C2 domain to confer Gαq 
binding (65) (Figure 5).  Along the same line, the C2 domain of the serine/threonine 
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kinase PKC-δ has been recently shown to bind phosphotyrosine (70), a function typically 
mediated only by protein tyrosine binding (PTB) or SH2 domains (71).   
Mechanism of PtdIns(4,5)P2 hydrolysis 
The catalytic TIM barrel is the most highly conserved region among PLC 
isozymes with 60-70% sequence identity (Figure 3).  The X and Y boxes fold together in 
an alternative pattern of α-helices and β-strands to constitute the TIM barrel (72).  The 
eight β-strands form the inner part of the barrel while the eight α-helices are located on 
the outer part of the barrel (72).  The structure of PLC-δ1 first revealed the organization 
of the active site and provided a mechanism for PtdIns(4,5)P2 hydrolysis (62).  The active 
site is located at the C-terminal ends of the β-strands and forms a solvent-accessible 
depression (62) (Figure 2).  
Surrounding the active site is a ridge of hydrophobic residues, Leu320, Tyr358, 
Phe360, Leu529, and Trp555, that facilitates the insertion of the catalytic domain onto the 
proximal membrane for optimal catalysis (62).  PLC-δ1 harboring substitution of bulky 
nonpolar residues to alanine had a similar Km to wild-type PLC-δ1 when PtdIns(4,5)P2 
hydrolysis was measured in detergent-mixed micelles (73).  In contrast, in phospholipid 
vesicles, PtdIns(4,5)P2 hydrolysis of the similar PLC-δ1 mutant enzymes was less 
sensitive to increased in surface pressure, which is consistent with a smaller portion of 
the enzyme able to penetrate the membrane bilayer (73).  These residues are conserved 
across the PLC family and located in the same orientation in PLC-β2 structures (67, 68), 
indicating that the hydrophobic ridge likely performs a similar function in all PLC 
isoforms. 
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Previous biochemical work indicate that eukaryotic PLC enzymes preferentially 
hydrolyze PtdIns(4,5)P2, but can also hydrolyze PtdIns(4)P and to a much lesser extent 
PdtIns (45).  The buried Ins(1,4,5)P3 at the bottom of the active site of PLC-δ1 provides 
the structural basis for substrate recognition (62).  An extensive network of H-bonds and 
salt-bridge interactions between the side chains of Lys438, Lys440, Ser522, and Arg549 
with the 4’ and 5’ phosphorylated hydroxyl groups of the inositol ring favors the 
interaction with lipids phosphorylated at both positions, validating the preference of 
PLCs for PtdIns(4,5)P2 and therefore providing substrate specificity (62).  In addition, the 
aromatic ring of Tyr551 is parallel with the inositol ring and forms numerous van der 
Waals contacts with it (62) (Figure 2A). 
Ligation of the essential Ca2+ cofactor is achieved by surrounding acidic residues, 
Glu341, Glu390, Asp343, and Asn312 (62) (Figure 2A).  The importance of these 
residues is exemplified by the complete loss of PLC-δ1 activity after the substitution of 
Gly for Glu341 (74).  In addition to these electrostatic interactions, the Ca2+ ion is also 
ligated to the 2’-hydroxyl group of the inositol ring (62).  This H-bond interaction is 
essential for PLC activity since 2’-deoxy-PtdIns is insensitive to hydrolysis (62).  
Prokaryotic PLCs utilize basic residues to fufill the functional requirements of the 
calcium cofactor and thus are Ca2+-independent enzymes (75). 
PtdIns(4,5)P2 hydrolysis follows a general acid/base catalytic scheme (Figure 2B).  
The Ca2+ ion lowers the pKa of the 2-hydroxyl group in the inositol ring to facilitate its 
deprotonation and subsequent nucleophilic attack on the 1-phosphate by the general base 
Glu341 (73).  This first step leads to the formation of a cyclic intermediate, which is 
stabilized by His311 and the calcium ion by specific ligation of the 1-phosphate (62).  In 
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the second step of PtdIns(4,5)P2 hydrolysis, His356 utilizes a proton from a water 
molecule to promote the nucleophilic attack of water onto the pentavalent cyclic 
intermediate, leading to the formation of DAG as a leaving group and Ins(1,4,5)P3 (62). 
Mutation of either His311 or His356 abolishes PLC-δ1 activity (74, 76, 77). 
The residues highlighted above participating in substrate specificity, calcium 
coordination, and catalytic reaction, are strictly conserved across the PLC family (Figure 
3) and are positioned in similar orientation in PLC-β2 structures (67, 68), indicating that 
the mechanism of PtdIns(4,5)P2 hydrolysis is conserved throughout eurakyotic PLC 
enzymes.  Furthermore, these results also support the contention that isozyme differences 
in enzymatic specificity are not controlled by differences in catalysis, but rather by 
differences in isozyme-specific regulatory mechanisms (Figure 6). 
Part II: Phospholipase C subfamilies and regulation 
PLC-δ  isozymes 
The PLC-δ subtype is the evolutionary precursor of other PLC isoforms as it 
arose in early eukaryotes, such as yeast (Saccharomyces cerevisia and 
Schizosaccharomyces pombe) (78-80), slime moulds (Dictyostelium discoideum) (81), 
and plants (Arabidopsis thaliana) (82).  Mammals were thought to possess four PLC-δ 
isozymes (PLC-δ1, -δ2, -δ3, and -δ4); however, further studies indicated that PLC-δ2 
was a homologue of PLC-δ4 (83), leaving the PLC-δ family with three isozymes (PLC-
δ1, -δ3, and -δ4).  The PLC-δ isoforms differ with regards to cellular distribution, 
activities, biochemical properties, and involvement in human disease. 
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The expression of PLC-δ isozymes has been detected both in numerous animal 
tissues as well as cultured cell lines, and their individual expression profiles vary greatly 
(84).  PLC-δ1 mRNA has been detected in rat skeletal muscle, spleen, testis, lung, and 
astroglial cells of the brain.  PLC-δ3 and-δ4 are ubiquitously expressed in diverse rat 
tissues such as kidney, cardiac muscle, aorta, spleen, testis, and brain (84). 
The subcellular localization of PLC-δ isozymes has been shown to vary 
dramatically.  PLC-δ1 is mainly a cytoplasmic protein, whereas PLC-δ3 is detected in the 
membrane fraction.  PLC-δ4 is mainly located in the nucleus and its expression is 
directly linked with the cell cycle.  Differences in subcellular localization of the PLC-δ 
isozymes lead to selective function for each isozyme. 
Regulation 
Although three PLC-δ isozymes are known, only PLC-δ1 is well characterized.  
The critical steps necessary to enhance the enzymatic activity of PLC-δ isoforms are 
membrane anchoring and substrate access.  Therefore, factors modulating the association 
of PLC-δ isoforms with the membrane and/or with its substrate, PtdIns(4,5)P2, alter the 
phospholipase activity of PLC-δ isoforms.  The two crystal structures of PLC-δ1 
provided the framework necessary to understand the regulation of PLC-δ isozymes.  
PLC-δ isoforms encode a PH domain, four EF hands, a catalytic TIM barrel formed of an 
X and Y box, followed by a C2 domain.  The PH domain of PLC-δ1 is mobile relative to 
the remainder of the protein and the two portions were independently crystallized and 
their structures determined (62, 65) (Figure 4). 
The structure of the PH domain of PLC-δ1 in complex with Ins(1,4,5)P3 
highlighted its capacity to bind phospholipids with high affinity and therefore serve as an 
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anchor point for PLC-δ isoforms at the plasma membrane (85) (Figure 4).  PH domains 
are typically highly polarized structures with a positively charged face interacting with 
the negatively charged inner face of the plasma membrane.  Consistent with this idea, the 
binding site for the soluble head group of PtdIns(4,5)P2, Ins(1,4,5)P3, is located at the 
center of this positively charged region, opposite to the C-terminal α-helix.  The residues 
coordinating Ins(1,4,5)P3 are found in the β1/β2 and β3/β4 loops of the PH domain of 
PLC-δ1 (85).  These loops are poorly conserved among PH domain and consistent with 
this observation the residues ligating the phospholipids are not conserved between PLC 
subfamilies, suggesting that the N-terminal PH domain is not functionally redundant (60). 
Although the binding of the PH domain of PLC-δ1 to PtdIns(4,5)P2 is well 
characterized, the membrane-binding properties of other PLC-δ isozymes are less 
understood.  The sequence of the PH domain for PLC-δ3 and -δ4 shares relatively high 
conservation with the PH domain of PLC-δ1 (33 – 38% identity) (66).  Furthermore, the 
residues involved in binding PtdIns(4,5)P2 are mostly conserved across PLC-δ isozymes, 
suggesting that all PLC-δ isozymes bind PtdIns(4,5)P2 through their PH domain.  The 
affinities of phospholipid binding are likely to vary among PLC-δ isozymes because the 
residues ligating Ins(1,4,5)P3 are not strictly conserved.  Consistent with this idea, the PH 
domain of PLC-δ4 shows lower affinity for PtdIns(4,5)P2 both in vitro and in intact cells 
than the PH domain of PLC-δ1 (86).  In addition, while PLC-δ1 is localized at the plasma 
membrane, PLC-δ4 only shows limited localization at the plasma membrane and strongly 
associates with the membrane of the endoplasmic reticulum (ER) (86).  This shift in 
subcellular localization does not solely rely upon the PH domain as deletion of the PH 
domain does not abrogate the subcellular localization of PLC-δ4 (86). 
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Several studies have highlighted the physiological and functional role of the PH 
domain in modulating the phospholipase activity of PLC-δ isoforms.  Indeed, the PH 
domain of PLC-δ isoforms has been proposed to facilitate a scooting mode of hydrolysis 
(Figure 4).  In this model, PLC-δ isoforms first bind to phospholipids at a noncatalytic 
site, the PH domain, that anchors PLC-δ isoforms at the plasma membrane during 
catalysis (87).  Once attached, PLC-δ isoforms then bind and cleave a second molecule of 
phospholipid at the catalytic site.  This dual substrate binding site model allows PLC-δ 
isoforms to hydrolyze numerous PtdIns(4,5)P2 molecules during a single binding event at 
the membrane interface.  In addition this process also allows feedback regulation of the 
enzymatic activity of PLC-δ isoforms through decreases in local PtdIns(4,5)P2 
concentration.  Experimental evidence for this model is provided by the concentration-
dependent increase in PLC-δ1 activity after addition of PtdIns(4,5)P2, but not PtdIns(4)P 
(87).  Furthermore, truncation of the PH domain, substitution at residues ligating 
PtdIns(4,5)P2, or competitive addition of Ins(1,4,5)P3 impaired PtdIns(4,5)P2-stimulated 
PLC-δ1 activity, but did not affect the catalytic function of PLC-δ1 (88). 
The high affinity and selective interaction between PtdIns(4,5)P2 and the PH 
domain of PLC-δ1 was exploited to generate a fluorescent probe to monitor local 
phospholipid signaling.  To this end, the PH domain of PLC-δ1 in isolation was fused to 
green fluorescent protein (GFP) and used as a fluorescent indicator for PdtIns(4,5)P2 in 
living cells (89).  Studies using this fusion protein revealed the localization and dynamics 
of PtdIns(4,5)P2 in living cells.  Later studies utilized an enhanced GFP-tag to refine the 
cellular localization of PtdIns(4,5)P2 to distinct regions of the plasma membrane, such as 
membrane ruffles.  This was the first indication that PtdIns(4,5)P2 could associate with 
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the cytoskeleton.  It was subsequently shown that PtdIns(4,5)P2 could bind and modulate 
many actin-regulatory proteins, including gelsolin, cofilin, profilin, the Arp2/3 complex, 
and Wiskott-Aldrich syndrome protein (WASP) (90).  In addition, the local concentration 
of PtdIns(4,5)P2 regulates the adhesion between the plasma membrane and cytoskeletal 
structure, thereby serving as a second messenger itself (91). 
Additional studies indicate that interactions outside those mediated by 
PtdIns(4,5)P2 binding are important for membrane association of PLC-δ isoforms.  
Indeed, the C2 domain has been proposed to mediate Ca2+-stimulated membrane 
association of PLC-δ isoforms, as the crystal structure of PLC-δ1 reveals the existence of 
three Ca2+ binding regions (CBRs) in the loops of the C2 domain (69, 92) (Figure 4).  
Membrane binding studies with isolated C2 domains from PLC-δ1, -δ3, and -δ4 indicate 
that Ca2+ binding to the CBRs switches the electrostatic potential of the C2 domain to 
favor non-specific electrostatic interactions with the plasma membrane (93).  In addition, 
the C2 domains of PLC-δ1 and -δ3 form a protein-Ca2+ complex with the anionic lipid 
phosphatidylserine (PS) to target these PLCs to specific regions of the plasma membrane 
(94).  In contrast, the C2 domain of PLC-δ4 lacks two of the four aspartic acid residues 
coordinating Ca2+ and does not exhibit Ca2+-dependent translocation to PS-enriched 
regions of the plasma membrane (93).  Together these studies suggest that the C2 domain 
is essential in regulating the subcellular localization of PLC-δ isozymes as a function of 
Ca2+. 
To date, the only validated activator that directly enhances the activity of PLC-δ 
isoforms is calcium ions.  Specifically, reconstitution assays using permeabilized cells 
depleted of PLCs have shown that the phospholipase activity of PLC-δ1, but not PLC-β1 
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or PLC-γ1, is stimulated in a Ca2+-concentration dependent manner at physiological 
concentrations (10 nM to 10 µM), indicating that Ca2+ alone is sufficient to promote 
increased phospholipase activity of PLC-δ isoforms (95, 96).  The molecular basis for 
this activation remains unknown, but studies have suggested that Ca2+-mediated 
activation of PLC-δ isoforms can be further potentiated through interaction with other 
proteins. 
Several lines of evidence suggest that PLC-δ isoforms are regulated by G-protein 
mediated signaling.  For example, stimulation of the α1-adrenergic receptor was 
proposed to result in activation of PLC-δ1 through a direct interaction with the atypical 
G-protein transglutaminase II, GαH (97).  Additional studies indicate that G-protein 
coupled receptor (GPCR) indirectly stimulate the lipase activity of PLC-δ isoforms 
through activation of additional signaling pathways selective for other PLC isoforms.  
For example, inositol phosphate production downstream of the angiotensin II type 1 
receptor (AT1R) requires activation of PLC-β isoforms via Gαq/11 and is potentiated by 
the interaction between RalA and PLC-δ1 (98, 99).  In this example, PLC-δ1 serves as 
amplifier of signaling initiated by other PLC isoforms. 
Physiological relevance 
The biological functions of PLC-δ isoforms have been studied through targeted 
gene disruption of individual PLC-δ isoforms in mice. 
PLC-δ1 null mice exhibit a hairless phenotype that is reminiscent of nude mice, in 
which the loss of function of Foxn1, a member of the winged helix/forkhead family of 
transcription factors, leads to hair loss and an inborn dysgenesis of the thymus (100).  In 
fact, PLC-δ1 was identified as a Foxn1-inducible gene that regulates the expression of 
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hair keratins.  However, the molecular mechanisms by which PLC-δ1 regulates hair 
keratin expression remain to be identified.  In addition to marked hair loss, PLC-δ1 null 
mice display symptoms of skin inflammation (101).  Exogeneous expression of PLC-δ1 
attenuated (LPS)-induced upregulation of IL-1β, a pro-inflammatory cytokine.  IL-1β 
typically induces the expression of IL-6, which promotes keratinocyte proliferation.  It is 
likely that lack of PLC-δ1 in keratinocytes results in aberrant production of IL-1β and 
subsequent upregulation of IL-6 expression, leading to skin inflammation and epidermal 
hyperplasia.  Together, these results suggest that PLC-δ1 regulates homeostasis of the 
immune system in the skin. 
Although PLC-δ1 localization is primarily cytoplasmic, PLC-δ1 contains both 
nuclear export and import sequences that allow it to shuttle between the nucleus and the 
cytoplasm (102).  Further studies demonstrate that PLC-δ1 accumulates in the nucleus at 
the G1/S boundary of the cell cycle, and its accumulation is positively correlated with the 
level of nuclear PtdIns(4,5)P2 (103).  In addition, depletion of PLC-δ1 in the nucleus 
delays the completion of S phase and transition into G2/M phase, leading to decreased 
cell proliferation and growth rate (104).  Levels of cyclin E, a key regulator of the G2/M 
transition, are also elevated (104).  Together these results show that PLC-δ1 modulates 
nuclear phospholipid metabolism that is critical for normal cell cycle progression.  
Consistent with this idea, PtdIns(4,5)P2 inhibits histone H1-mediated basal transcription 
initiated by RNA polymerase II through a direct interaction with the C-terminal tail of 
histone H1 (105). 
Several studies implicate PLC-δ1 in neurodegenerative disorders (106).  
Specifically, in Alzheimer patients, PLC-δ1 accumulates in the neurofibrillary tangles 
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(107).  In addition, PLC-δ1 protein overexpression is associated with high enzymatic 
activity in Alzheimer patients (107), suggesting that PLC-δ1-mediated phospholipid 
turnover plays an important role in the development of this neurodegenerative disease.  A 
recent study indicated a direct link between the activation of the N-methyl-D-aspartic 
acid (NMDA) receptor under oxidative stress conditions and an increase in PLC-δ1 
protein levels (108).  This provides a molecular link between neurons responding to 
oxidative stress and the accumulation of neurofibrillary tangles and senile plaques in 
Alzheimer’s disease. 
PLC-δ1 has recently been identified as a tumor suppressor, located at 
chromosome 3p22, an important tumor suppressor locus.  Indeed, downregulation of 
PLC-δ1 in esophageal squamous cell carcinoma is associated with promoter 
hypermethylation and frequent allelic loss at the PLC-δ1 locus (109).  In other tissues, 
epigenetic regulation of PLC-δ1 has been linked to cancer progression.  For example, 
PLC-δ1 expression is greatly reduced through hypermethylation of its gene in both 
gastric cancer cell lines and primary tumors.  Furthermore, this gene silencing is 
associated with later stages of gastric cancer (110).  Moreover, the same study showed 
that PLC-δ1 decreased cell motility, suggesting that PLC-δ1 activity directly affects 
proteins regulating cytoskeletal rearrangement, such as actin-regulated protein, Rho 
GTPases, or metalloprotease proteins (110).  Together, these studies indicate that PLC-δ1 
is frequently silenced by epigenetic alteration in a tumor-specific manner.  Another study 
reported that mRNA expression for PLC-δ1 and -δ3 directly correlates with the 
metastatic state of human breast cell lines, such that PLC-δ1 and -δ3 are more highly 
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expressed in transformed cell lines (111).  This study also supported an important role for 
PLC-δ1 and -δ3 in cell growth and migration (111). 
Disruption of the PLC-δ3 gene did not lead to any observed abnormality in mice.  
However, disruption of both PLC-δ1 and PLC-δ3 resulted in embryonic lethality caused 
by developmental failure of the placenta (112).  Further analyses indicated that the 
labyrinth trophoblast layer of the placenta in the PLC-δ1/PLC-δ3 double knock-out 
mouse, necessary for the exchange of oxygen, nutrients and waste between the mother 
and the embryo, was poorly vascularized and had reduced cell proliferation and abnormal 
cell death (112).  These results clearly indicate that PLC-δ1 and PLC-δ3 are required for 
normal morphogenesis and function of the placenta in mice. 
Disruption of the PLC-δ4 gene leads to male infertility, whereas female mice 
remain fertile.  In vitro fertilization studies indicated that sperm from PLC-δ4 deficient 
mice were unable to maintain a sustained influx of calcium, which is a critical component 
of the interaction of the sperm with the zona pellucida for the acrosome reaction to occur 
(113).  These results highlight an important role for PLC-δ4 in the early steps of 
fertilization. 
PLC-β  isozymes 
There are four PLC-β isozymes (-β1, -β2, -β3, and -β4) that differ with respect to 
their expression pattern and specific regulation.  While PLC-β1 is highly expressed in the 
cerebral cortex and hippocampus (114), PLC-β2 expression is more limited to 
hematopoietic cells (115).  PLC-β3 is expressed in the brain, liver, and parotid gland 
(116), while PLC-β4 expression is enriched in the cerebellum and the retina (117).  PLC-
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β isozymes are structurally characterized by the unique presence of a C-terminal coiled-
coil domain that has been shown to mediate dimerization and effector binding (118, 119). 
Regulation 
PLC-β isozymes function as effectors of heterotrimeric G-proteins downstream of 
GPCR belonging to the rhodopsin superfamily of seven transmembrane receptors (class 
A), including M1, M3, and M5 muscarinic cholinergic, α1 and β2-adrenergic, H1 
histamine, vasopressin type 1, 5-HT2 serotonergic, calcitonin, metabotropic glutamate 
group 1, and many others.  Agonist-stimulated receptor activation of PLC-β isozymes is 
mediated by both the α subunit members of the Gq subfamily (120) and by βγ subunits 
(121). 
The Gαq family contains four members (q, 11, 14, and 16) that are closely related 
in sequence.  Like Gαs and Gα12 families, Gαq members lack the cysteine residue near 
the carboxyl terminus that is the site of pertussis-toxin (PTX) catalyzed ADP-ribosylation 
of members of the Gαi subfamily.  All four Gαq proteins stimulate the activity of PLC-β 
isozymes both in cells (122, 123) and with purified components (116, 124).  PLC-β1 and 
-β3 were found to be preferred substrates for Gαq-stimulated PLC activity, while Gαq 
modestly increases PLC-β2 activity (124-126).  Although the interface between Gαq and 
PLC-β isoforms was originally thought to be contained within the isozyme-specific CT 
domain (118, 119, 127), the recent crystal structure of Gαq complexed with PLC-β3 (65) 
reveals a novel interface outside the CT domain (Figure 5).  In this complex, Gαq 
interacts with a unique extension of the C2 domain of PLC-β3, which forms a helix-turn-
helix motif, as seen in other Gαq effectors, such as p63RhoGEF (128, 129) and G 
protein-coupled receptor kinase 2 (GRK2) (130).  In all three effectors, the helical motif 
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interacts with switch 2 and α3 from Gαq and is necessary and sufficient to confer Gαq 
binding.  These results strongly indicate that the CT domain of PLC-β3 does not directly 
contact Gαq, as previously described.  The unique helix-turn-helix C2 domain extension 
is only present in PLC-β isozymes, suggesting that other PLCs are not regulated by Gαq. 
Reconstitution assays with purified PLC-β from turkey erythrocytes show Gβγ-
dependent stimulation of PLC-β turkey, indicating that PLC-β isoforms can also be 
activated by the βγ dimer (131-133).  The Gβγ dimer can bind to and activate all PLC-β 
isozymes, except PLC-β4 (134).  The relative sensitivity of PLC-β isozymes to Gβγ 
differs from that of the Gαq subunit, such that PLC-β1 is the least sensitive to Gβγ while 
PLC-β2 is the most sensitive to activation by Gβγ (134, 135).  The binding interface 
between PLC-β isoforms and Gβγ remains elusive although several studies pointed 
towards engagement of the N-terminal PH domain and part of the catalytic TIM barrel 
(136, 137).  Alternatively, a recent study combining evolutionary analysis and 
biochemical studies proposed a binding interface within Gβ1γ2 specific for PLC-β2 
(138). 
Rac proteins, members of the Rho family of small GTPases, also activate PLC-β 
isoforms (139), through a portion of PLC-β isoforms distinct from regions involving Gα 
and Gβγ regulation (140).  Biochemical (141) and structural (63) evidence indicate that 
Rac directly engages the N-terminal PH domain to recruit PLC-β isozymes to the plasma 
membrane (142) (Figure 5).  Similar to Gβγ, Rac binds differentially to PLC-β isozymes 
with the highest affinity for PLC-β2, then PLC-β3, and no detectable binding to PLC-β1 
or PLC-β4 (141).  The specific effects of each PLC-β activator, heterotrimeric G-protein 
and Rac GTPases, remain elusive.  However, using fluorescence recovery after 
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photobleaching (FRAP), a recent study found differential recruitment of PLC-β2 at the 
plasma membrane by Rac, Gαq, and Gβγ.  While Rac recruits PLC-β2 to specific regions 
of the plasma membrane, Gβγ recruitment of PLC-β2 is more diffuse throughout the 
plasma membrane (143).  These results indicate that distinct activators differentially 
regulate the spatiotemporal activation of PLC-β isozymes. 
Structural and biochemical studies reveal that dimerization of PLC-β isozymes is 
mediated by its CT domain, composed of three α-helices packed together to form a 
coiled-coil (119).  The functional relevance of PLC-β dimerization is not understood, but 
it is likely that the CT domain favors interaction with proximal membranes due to its 
large electropositive potential (119).  Membrane recruitment is a prerequisite to all PLC 
isoforms for proper substrate hydrolysis.  Therefore, like the PH domain in PLC-δ 
isoforms, the CT domain of PLC-β isoforms provides a direct anchor point to the plasma 
membrane and might potentiate the enzymatic activity of PLC-β isoforms through 
localization. 
Signaling through PLC-β isoforms not only occurs at the plasma membrane, but 
also in the nucleus.  Hydrolysis of PtdIns(4)P and PtdIns(4,5)P2 by nuclear PLC-β1 
established the existence of nuclear PLC signaling (144).  Further studies indicated that 
PLC-β1 is the most abundant PLC-β isozyme in the nucleus, followed by PLC-β3, -β2, 
and -β4 and that they localize to the inner nucleus compartment (145).  The significance 
of this autonomous pathway in the nucleus needs further clarification, but several studies 
suggest a role for PLC-β1 in controlling cell cycle progression, specifically at the G2/M 
boundary (146, 147). 
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PLC-β1 was the first GTPase-Activating Protein (GAP) identified for 
heterotrimeric G proteins (148).  PLC-β isoforms stimulate the hydrolysis of Gαq-bound 
GTP, leading to the deactivation of Gαq.  The recent crystal structure of the PLC-β3•Gαq 
complex indicates that the structural requirements for GAP activity lies within an 
isoform-specific insertion between the third and fourth EF hands of PLC-β isoforms (65).  
Within this loop, Asp260 of PLC-β3 directly interacts with the catalytic Gln209 of Gαq 
and stabilizes the pentameric transition state necessary for hydrolysis (149).  This 
GTPase mechanism is identical to the one observed with regulator of G-protein (RGS) 
proteins (150). 
PLC-β isoforms are the only known proteins to act simultaneously as an effector 
and deactivator of Gαq signaling.  In parallel, p115RhoGEFs serve the analogous role for 
Gα13 signaling (151).  This dual function unique to PLC-β isozymes allows this enzyme 
to serve as a kinetic scaffold to potentiate receptor signaling through Gαq (152).  In this 
model, PLC-β isoforms rapidly deactivate Gαq, which in turn increases the association 
rate constant of Gαq•GDP with its cognate GPCR.  Binding of Gαq•GDP to the receptor 
promotes the GEF activity of the receptor to stimulate the activation of PLC-β isoforms 
by Gαq•GTP.  The above cycle is then repeated to allow for amplification of PLC-β-
mediated signalling.  In addition, the GAP efficiency of PLC-β isoforms allows Gαq to 
virtually never dissociate from the receptor and constantly accelerate the G-protein cycle.  
The mechanism by which this cycle is turned off is not well understood, but the Gβγ 
subunit is likely a major component needed for deactivation as it is required for efficient 
heterotrimeric G-protein association with the receptor (153).  In light of this idea, it 
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would be very valuable to investigate the role of Gβγ in the deactivation of Gαq mediated 
by PLC-β isoforms as Gβγ also stimulates the activity of PLC-β isoforms. 
Physiological relevance 
PLC-β1 null mice experience sudden death preceded by epileptic seizures, that 
resembled a GABAA-antagonist response, suggesting that PLC-β1 is essential for the 
normal functioning of the inhibitory neuronal pathway (154).  A recent study suggested 
that PLC-β1 regulates the plasticity of M1-muscarinic receptor expression in the adult 
neocortex, resulting in an imbalance between the muscarinic and dopaminergic systems, 
as often seen in schizophrenia (155). 
PLC-β2-deficient mice are viable but display a reduction in chemoattractant-
induced inositol phosphate accumulation, intracellular Ca2+ levels, superoxide 
production, and cell surface MAC-1 expression, suggesting that PLC-β2 is critical for 
many chemoattractant-elicited signals in leukocytes (156).  In contrast, neutrophils 
lacking PLC-β2 exhibit higher chemotaxis, suggesting that the PLC-β2 signaling 
pathway inhibits chemotaxis (157). 
PLC-β3 null mice demonstrate higher sensitivity to morphine, suggesting that 
PLC-β3 suppresses µ-opioid receptor signaling through its Gβγ interaction (158).  PLC-
β3 deficiency leads to premature death in mice and is associated with lymphomas and 
carcinomas (159).  In addition, PLC-β3-deficient mice develop myeloproliferative 
disease due to the loss of Stat5 regulation by the PLC-β3•SHP-1 complex (159).  
Moreover, PLC-β3 null mice showed complete defects in scratching responses initiated 
after addition of a H1-specific agonist while retaining deep pain response, indicating that 
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in sensory signaling, PLC-β3 activation downstream of the histamine H1 receptor is a 
major component of the in vivo itch response to histamine (160). 
PLC-β4 null mice develop ataxia (161), a motor defect, and impaired visual 
processing (154).  A recent genome-wide profiling study of pancreatic cancer revealed a 
genetic substitution of Arg254 in PLC-β4 (162).  This substitution diminishes the GAP 
activity of PLC-β isozymes and therefore abolishes the capacity to deactivate Gαq, 
leading to aberrant Gαq-mediate signaling (65).  These results indicate that PLC-β 
isoforms are tumor suppressors important for adequate cell proliferation. 
PLC-γ  isozymes 
There are two mammalian PLC-γ isozymes (PLC-γ1 and PLC-γ2).  PLC-γ1 is 
expressed ubiquitously while PLC-γ2 expression is restricted to cells of the 
haematopoietic system (114).  PLC-γ isozymes are structurally characterized by a large 
insertion between the two halves of the catalytic TIM barrel and composed of an ordered 
region containing a split PH domain, two SH2 domains and a SH3 domain.  This domain 
organization is unique to PLC-γ isozymes and engenders PLC-γ selective activators, such 
as receptor and non-receptor tyrosine kinases. 
Regulation 
Almost all growth factor receptors with intrinsic tyrosine kinase activity (RTKs) 
have been linked to stimulation of PLC-γ isozymes (163).  Agonist-binding stimulates 
dimerization and autophosphorylation of these RTKs on tyrosine residues exposed on the 
cytoplasmic side of the receptor, which creates docking sites for SH2-containing proteins 
like PLC-γ isozymes (164).  Specifically, autophosphorylation of Tyr766 in fibroflast 
growth factor receptor 1 (FGFR1) (165), Tyr992 in epidermal growth factor receptor 
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(EGFR) (166), and Tyr1021 in platelet-derived growth factor receptor (PDGFR) (167) 
confers a high-specificity interaction with the N-terminal SH2 (nSH2) domain of PLC-γ1 
(168, 169).  This interaction is essential for both membrane recruitment (170, 171) and 
tyrosine phosphorylation of PLC-γ1 (174, 175). 
RTKs stimulation phosphorylates PLC-γ1 at five residues, Tyr472, Tyr771, 
Tyr775, Tyr783, and Tyr1254 (176-178), which leads to increased catalytic activity of 
PLC-γ1 (179).  Recent studies highlight a discrepancy between the requirements for 
tyrosine phosphorylation in vitro versus in vivo.  Specifically, reconstitution assays with 
purified protein indicate that only phosphorylation of Tyr783 increases PLC-γ1 activity 
(172), whereas both Tyr775 and Tyr783 phosphorylation are necessary to increase lipase 
activity in intact cells (178).  Although the nature of this discrepancy remains unknown, 
evolutionary analysis indicate that Tyr783 is the primary regulatory residue for PLC-γ1 
activity because its conservation extends to Caenorhabditis elegans (worm), the 
primordial ancestor of PLC-γ isozymes, whereas Tyr775 first appears in arthropods 
(Aedes aegypti), then in chordates (Xenopus laevis).  The specific role of phosphorylated 
Tyr775 in intact cells remains elusive, but it likely acts in concert with Tyr783 to sustain 
PLC-γ1 activity. 
PLC-γ1 and PLC-γ2 can also be activated downstream of receptors that lack 
intrinsic tyrosine kinase activity, such as angiotensin II, bradykinin B2, and B-cell and T-
cell immunoreceptors (173-176).  In these cases, PLC-γ isozymes are phosphorylated by 
cytosolic tyrosine kinases in the context of large signaling complexes located at the 
plasma membrane.  In haematopoietic systems, the majority of receptors that activate 
PLC-γ isozymes via non-receptor tyrosine kinases are coupled to proteins containing 
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immunoreceptor tyrosine-based activation motifs (ITAMs) of consensus sequence 
DX2YXLX6–12YDXL (X=any amino acid). 
PLC-γ1 is the predominant isoform activated in T cells downstream of the T-cell 
antigen receptor (TCR, CD3) (177, 178).  The Src tyrosine kinases Lck, and to a lesser 
extent Fyn (179), phosphorylate the ITAM motifs within the TCR complex.  This recruits 
the T-cell specific ZAP-70 into the signaling complex through its tandem SH2 domains 
(180).  ZAP-70 tyrosine phosphorylates two adaptor proteins, LAT (181) and SLP-76 
(182), which act as scaffolding proteins.  PLC-γ1 is recruited to this membrane complex 
through its N-terminal SH2 domain binding LAT, while SLP-76 interacts with PLC-γ1 
through its SH3 domain (183-185).  Although the kinases responsible for directly 
phosphorylating PLC-γ1 remain undefined, phosphopeptide mapping studies indicate the 
major sites of PLC-γ1 tyrosine phosphorylation in human T cells are the same as those 
described for cells treated with growth factors (173). 
In contrast to T cells, cross-linking of the B-cell antigen receptor (BCR) results in 
tyrosine phosphorylation and activation of PLC-γ2 rather than PLC-γ1 (186).  The Src 
tyrosine kinases, Lyn and Fyn, phosphorylate ITAMs within the Igα–Igβ chains of BCR, 
resulting in recruitment, phosphorylation, and activation of Syk (187).  In turn, Syk 
phosphorylates the adaptor protein BLNK, also known as SLP-65 and BASH, resulting in 
its localization to the signaling complex (188).  BLNK interacts with both Btk and PLC-
γ2, via their SH2 domains (189).  The kinases Lyn, Syk, or Btk might be responsible for 
the phosphorylation of PLC-γ2 (190).  Phosphorylation of both Tyr753 and Tyr759 
appear to be essential for functional B-cell signaling (199). 
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The subject of this dissertation research is to elucidate the mechanism of 
phosphorylation-stimulated activation of PLC-γ isozymes and will be fully discussed in 
chapter three. 
Two additional mechanisms, which do not require tyrosine phosphorylation to 
increase the enzymatic activity of PLC-γ isozymes have been identified.  The first 
activation mechanism recruits PLC-γ isozymes to the plasma membrane via interaction 
between the N-terminal PH domain and the phospholipid PtdIns(3,4,5)P3 (64), whereas 
the second mechanism relies on the interaction of Rac GTPases with the split PH of PLC-
γ2, specifically, to increase lipase activity (191). 
PtdIns-3-kinase (PI3K) phosphorylates PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3, 
which functions as a specific ligand for the N-terminal PH domain of PLC-γ isozymes to 
mediate its translocation to the plasma membrane (64).  Studies using truncation 
constructs of PLC-γ1 indicates that PtdIns(3,4,5)P3 also binds to the cSH2 domain of 
PLC-γ1 (192), therefore, providing an additional anchor point to the plasma membrane.  
Several reports suggest that RTKs and PI3K synergize to amplify PLC-γ1-mediated 
signaling (64, 202). 
Recently, the Rac GTPases have been identified as novel activators of PLC-γ2 
with Rac2 being the most potent activator (193).  Rac2-stimulation of PLC-γ2 activity 
occurs in a nucleotide-dependent manner and requires the split PH domain of PLC-γ2 
(194).  The structural details of this interaction reveal that the switch regions of activated 
Rac2 directly engage the β5-strand and α-helix of the isolated split PH domain of PLC-γ2 
through hydrophobic interactions (191).  This interface is distinct from the engagement of 
Rac GTPases with the N-terminal PH domain of PLC-β isozymes (63), suggesting that 
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the interaction between Rac GTPases and PLC-γ2 is specific.  The molecular details 
leading to increased PLC-γ2 activity after Rac binding are currently unresolved, but they 
likely involve structural rearrangements of the X/Y-linker to facilitate substrate 
hydrolysis.  Although the physiological relevance of the Rac2/PLC-γ2 interaction 
requires further investigation, preliminary study indicates a role for Rac-stimulated PLC-
γ2 activation in platelets (195). 
Physiological relevance 
Animals homozygous for the PLC-γ1 null allele die by embryonic day 9 due to 
generalized growth failure (196) whereas PLC-γ2 null mice remain viable after birth 
(197, 198).  Closer examination of PLC-γ1 embryos indicates that the embryonic lethality 
might be attributed to the loss of both erythroid progenitors and endothelial cells (199).  
Both of these components are necessary for proper vasculogenesis and erythropoiesis 
(199).  Vascular endothelial growth factor (VEGF) activates PLC-γ1 via the RTKs FLT-1 
and FLK-1 (200).  During development, VEGF is produced and secreted by 
cardiomyocytes to enhance cardiac vascularization (200).  Furthermore, zebrafish model 
systems suggest that VEGF signaling through PLC-γ1 modulates cardiac contractility, as 
zebrafish deficient in functional PLC-γ1 protein lose ventricular contractility and are 
defective in vasculogenesis (200). 
Several studies implicate PLC-γ1 as a critical component of cellular 
transformation downstream of EGFR/erbB2 activation.  In particular, one report detected 
increased expression of PLC-γ1 in a number of EGF-dependent breast cancer tissues 
(201).  Interestingly, the majority of overexpressed PLC-γ1 was phosphorylated in 
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correlation with upregulation of both EGFR and erbB2, suggesting that PLC-γ1 activity 
was necessary to drive breast tumor formation (201). 
Angiogenesis and cell motility are two key components of tumor formation.  
These results indicate that the lipase activity of PLC-γ isoforms plays an important role in 
both processes, highlighting the central role of PLC-γ isozymes in metastatic tumors. 
PLC-ε  isozymes 
A fourth class of PLC isozymes, PLC-ε, was first discovered in Caenorhabditis 
elegans (202), while the mammalian homologue was later cloned by three independent 
groups (49, 50, 203).  A single isoform of PLC-ε has been reported and its expression is 
ubiquitous and highly enriched in the heart, liver, and lung (49).  PLC-ε is the largest 
PLC isozyme and contains an N-terminal cysteine-rich domain, followed by a CDC25 
domain, and two C-terminal Ras-associating domains (RA1 and RA2) in addition to the 
core PLC domains (204).  The unique structural architecture of PLC-ε allows it to 
integrate Ras and phospholipid signaling. 
Regulation 
CDC25 domains typically confer RasGEF function, which catalyzes the exchange 
of GDP for GTP on small GTPases of the Ras family, rendering them active (205).  The 
GTPase specificity of the CDC25 domain remains elusive, but several studies suggest 
that PLC-ε acts as GEF for Rap1 (206, 207), leading to enhanced Rap1-mediated PLC-ε 
activity in a feed-forward mechanism.  Specifically, in astrocytes, thrombin required the 
GEF activity of PLC-ε to activate Rap1 and elicit ERK1/2 activation to stimulate 
mitogenesis (208). 
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PLC-ε was discovered as a Ras-binding protein in C. elegans and possesses 
tandem RA domains in its C-terminus.  RA domains are effector sites for activated Ras 
small GTPases, suggesting that PLC-ε is a direct Ras effector.  Indeed, early studies 
reported that H-Ras and Rap1 bind to the RA2 domain in a GTP-dependent manner; 
binding of H-Ras to the RA1 domain has also been observed, but the affinity is much 
lower than the one measured for the RA2 domain (49).  A later study confirmed the 
ability of the RA2 domain to bind both H-Ras and Rap1b, whereas the RA1 domain 
showed binding to either protein (209).  These results were validated with the solution 
structures of the isolated and tandem RA1 and RA2 domains.  The RA1 domain presents 
an unfavorable electrostatic interface and lacks the residues necessary for Ras binding, 
while the RA2 domain had 8-fold higher affinity for H-Ras than Rap1 (210).  Cellular 
studies indicate that EGF increases PLC-ε activity through H-Ras and Rap1-mediated 
PLC-ε translocation to promixal membranes, which is dependent on an intact RA tandem 
(49, 50).  Specifically, H-Ras mediates the translocation of PLC-ε to the plasma 
membrane, while Rap1 mediates the translocation of PLC-ε to the perinuclear region 
(50).  While the detailed mechanism for Ras-mediated activation of PLC-ε is currently 
unknown, it likely involves translocation of PLC-ε to the plasma membrane through 
direct interaction of Ras with the RA2 domain to enable substrate hydrolysis. 
Early studies indicate that the co-transfection of Gα12/13 and PLC-ε lead to 
increased lipase activity, suggesting that PLC-ε is linked to Gα12/13-coupled GPCRs, such 
as LPA and thrombin receptors (203, 211).  Additional studies with intact cells (212) and 
purified components (213) validate that Gα12/13 stimulation of PLC-ε activity is mediated 
through a direct interaction between the small GTPase RhoA and PLC-ε through a unique 
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62-residue insert within the catalytic Y box.  Interestingly, RhoA is activated by two 
distincts group of Gα subunits downstream of GPCR activation.  Indeed, both Gα12/13 
and Gαq/11 family members stimulate RhoA activation (129).  It is therefore possible that 
PLC-β isoforms are also stimulated by Gαq/11 and that phospholipid signaling 
downstream of Gα12/13 receptors could be potentiated by activation of two PLC isozymes, 
PLC-β and PLC-ε.  The physiological relevance and implications for such synergy 
between PLC isozymes requires further investigation, but it has been suggested that PLC-
β3 mediates acute phospholipid signaling, whereas PLC-ε mediates sustained signaling 
(214). 
Along the same line, H-Ras and RhoA stimulate PLC-ε activity using two distinct 
regions of PLC-ε: the C-terminus and a portion of the Y-box, respectively.  Although 
structural information on full-length PLC-ε is lacking, it is safe to assume that these two 
regions will be sufficiently distant from one another to promote simultaneous binding of 
both small GTPases to PLC-ε.  Reconstitution assays with purified components indicate 
that dual activation of PLC-ε by H-Ras and RhoA results in an additive effect when 
compared to independent stimulation of PLC-ε activity by either H-Ras or RhoA (215).  
The same study also demonstrates that PLC-ε activity is more sensitive to stimulation by 
H-Ras following RhoA binding, suggesting a possible temporal order of binding between 
the two GTPases (215).  Together, these results indicate that PLC-ε is a spatial and 
temporal convergent point of Ras and Rho signaling. 
PLC-ε is additionally activated by the Gβγ dimer, although the fold-stimulation of 
PLC-ε activation is less than the one mediated by Gα12/13 (216).  In this study, ectopic 
expression of Gβγ lead to increased PLC-ε-induced accumulation of inositol phosphates.  
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These results contrast with another study, which could not detect Gβγ-dependent 
stimulation of PLC-ε activity using purified components, at low concentrations of Gβγ 
(100 nM) (49).  In intact cells, Gβγ-induced PLC-ε activity is independent of a functional 
RA domain, suggesting that the putative binding site for Gβγ is distinct from Ras small 
GTPases (216).  In addition Gβγ-stimulated PLC-ε activity is abolished by the addition of 
Gαi or the C-terminus of GRK2, suggesting that free Gβγ is necessary for PLC-ε 
activation.  The interface between Gβγ and PLC-ε remains to be identified and is 
speculated to involve the PH domain, as this domain has been shown to be involved in 
Gβγ-stimulated PLC-β activity (136, 137). 
Agonist-stimulation of the β2-adrenergic receptor or forskolin stimulation of 
adenylyl cyclase (AC) leads to transient or rapid, respectively, increases in PLC-ε 
activity, mediated through Gαs (217).  The signaling protein mediating the AC-dependent 
PLC-ε activation was identified to be Rap2b, through the cAMP-activated RapGEF Epac 
(217).  A later study found that the analogous mechanism of PLC-ε activation was in 
place downstream of the M3 muscarinic acetylcholine (mAChR) receptor, such that 
overexpression of PLC-ε enhanced mAChR-stimulated phospholipid signaling, while 
catalytically inactive PLC-ε terminated the potentiating effects of Gαs (218). 
Physiological relevance 
Targeted disruption of PLC-ε in mice leads to developmental defects of the aortic 
and pulmonary cardiac valves, indicating that PLC-ε plays a central role in heart 
development and function (219).  This phenotype is similar to one observed for mice 
deficient in heparin-binding epidermal growth factor, a ligand for EGFR (220), 
suggesting that growth factor mediated activation of PLC-ε is a relevant signaling 
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pathway for heart development.  Mice homozygous for PLC-ε deletion have reduced 
cardiac contraction due to decreased β-adrenergic receptor (β-AR)-stimulated transient 
Ca2+ production, therefore rendering these animals susceptible to hypertrophy (221).  An 
earlier study linked activation of β-AR with increased cAMP levels, which in turn 
activated the RasGEF Epac to stimulate Rap2B activity, leading to PLC-ε activation 
(217).  Targeted inactivation of PLC-ε in the skin under chemical carcinogenesis 
dampened cell proliferation and markedly reduced incidence of skin squamous tumors 
(222), suggesting that PLC-ε might be a tumor suppressor gene.  Consistent with this 
idea, microarray analysis of patients with sporadic colorectal cancer indicated that the 
PLC-ε gene was significantly down-regulated in these patients (223). 
Another study used positional cloning to identify the genetic basis for nephrotic 
syndrome (224).  They found that mutations in PLC-ε gene that lead to loss of PLC-ε 
function, either through truncated or missense mutations, caused an arrest of normal 
glomerular development, leading to early-onset nephrotic syndrome (224).  Zebrafish 
with knockdown of PLC-ε failed to develop a functional barrier, suggesting that the role 
of PLC-ε in the maintenance of the podocyte filtration barrier is conserved throughout 
evolution (224). 
PLC-ζ  isozymes 
PLC-ζ was first isolated and cloned from human and mouse testis (51).  PLC-ζ is 
a gamete-specific PLC that is only expressed in spermatids (51).  PLC-ζ is the smallest 
PLC isozyme and the only one that lacks the N-terminal PH domain.  The absence of this 
domain suggests that PLC-ζ is more closely related to plant PLCs (225), than the 
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mammalian PLC-δ isozymes (33% sequence identity with PLC-δ1) (51).  Fluorescence 
microscopy studies indicate that PLC-ζ accumulates in the pronucleus (226). 
Regulation 
Enzymatic characterization of PLC-ζ using purified proteins indicates that the 
EC50 of PLC-ζ for calcium-dependent PtdIns(4,5)P2 hydrolysis is ~100-fold lower than 
that of PLC-δ1, suggesting that PLC-ζ exhibits the highest sensitivity to Ca2+ relative to 
other PLC isoforms (227).  Indeed, PLC-ζ activity was stimulated with Ca2+ 
concentrations as low as 10 nM and reached a maximum at 1 µM (227), suggesting that 
PLC-ζ can be activated in the absence of extracellular stimulus.  In addition, deletion of 
the EF-hands or the C2 domain abrogated this Ca2+-dependent PLC-ζ activation, 
indicating a potential role for this domain in regulating PLC-ζ activity (227-229).  
However, structural knowledge from PLC-δ1 (62) and PLC-β2 (67, 68), indicates that 
both the EF-hands and the C2 domain provide a supportive role in the overall structural 
integrity of the PLC isozymes.  Indeed, the C2 domain makes extensive hydrophobic 
contacts with the catalytic TIM barrel.  Therefore, deletion of either domain could 
compromise the overall structure of PLC-ζ resulting in impaired substrate hydrolysis. 
PLC-ζ contains two nuclear localization signals (NLS): the first one is in the C-
terminus of the X domain, residue 299 to 308 (KFKILVKNRK), and the second one is 
located in the X/Y-linker, residue 374 to 381 (KKRKRKMK) (230).  Point mutations 
within the two regions abrogate PLC-ζ nuclear localization, but these mutant enzymes 
retain the ability to initiate Ca2+ signaling (230). 
To date, it is unclear how PLC-ζ targets to the plasma membrane, where its 
substrate, PtdIns(4,5)P2 resides.  The C2 domain is an attractive candidate for such 
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function as it has been shown to bind phospholipids in other proteins (231).  Clearly, 
more work is needed to delineate the molecular components regulating PLC-ζ activation. 
Physiological relevance 
Injection of RNA encoding PLC-ζ in mouse eggs induces intracellular Ca2+ 
oscillations and egg activation (51).  Additional fluorescent studies indicate that PLC-ζ 
located in the perinucleus disperses to the cytoplasm upon nuclear envelope breakdown 
and translocates back into the nucleus after cleavage, in a cell-cycle dependent manner 
(232).  The shuttling of PLC-ζ in and out of the nucleus coincides with Ca2+ oscillations, 
such that when PLC-ζ is associated with the perinucleus in the interphase, no Ca2+ is 
detected, whereas in the mitotic phase, PLC-ζ translocates to the cytoplasm and initiates 
Ca2+ oscillations (232). 
PLC-η  isozymes 
In 2005, four independent groups discovered a novel class of PLC isozymes, 
PLC-η (52, 53, 233, 234).  To date, two isoforms of PLC-η are known: PLC-η1 and 
PLC-η2 (52, 53, 233, 234).  Expression of both PLC-η isoforms is highly enriched in 
neuron-enriched regions of the brain, suggesting a role for this PLC isozyme in neuronal 
development (233, 234).  Evolutionary, PLC-η isozymes are most closely related to PLC-
δ (52).  PLC-η isozymes are structurally similar to PLC-δ isozymes with the addition of 
an extended C-terminus after the C2 domain where a putative PDZ domain is located 
(53).   
Regulation 
Harden et al. first showed that PLC-η2 activity was stimulated by co-expression 
with Gβγ subunit after transfection in COS-7 cells (53).  Gβγ subunits also stimulate 
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PLC-β2 and PLC-ε.  Combined analysis from two independent studies showed that PLC-
β2 is the preferred Gβγ substrate, followed by PLC-η2, and finally PLCε (53, 235).  
Additional studies with purified proteins indicates that the N-terminal PH domain and the 
C-terminal extension are dispensable for Gβγ-induced PLC-η2 activity, suggesting that 
the interface between PLC-η2 and Gβγ lies within the catalytic core of PLC-η2 (235).  
As seen with other PLC isozymes, Gβγ-dependent PLC activity depends on the presence 
of free Gβγ dimer, as both Gαi and the C-terminus of GRK2 inhibit this activation in a 
dose-dependent manner (235). 
Conflicting reports exist on the subcellular localization of PLC-η.  Using 
fluorescently-tagged PLC-η and fractionation studies, one report indicated that PLC-η is 
located both in the cytoplasm and at the plasma membrane (233).  In contrast, another 
report used immunofluorescence and fractionation studies to conclude that PLC-η exists 
predominantly at the plasma membrane (234).  The later study also showed that deletion 
of the N-terminal PH domain dislocalized PLC-η from the plasma membrane to the 
cytosol, indicating that the PH domain of PLC-η functions as a localization signal for the 
plasma membrane, analogous to the PH domain of PLC-δ isozymes (234).  Further 
studies are necessary to confirm the role of the PH domain of PLC-η as a membrane 
anchor for this class of PLCs and to determine the specificity of interaction with the 
phospholipids. 
PLC-η isozymes contain a class II PDZ-binding domain at their C-terminus 
(sequence LLRL) (53).  PDZ domains are protein-protein interaction domains that 
typically recognize a short sequence at the C-terminus of the protein, but can also 
recognize internal sequences whose structure resembles a terminus (236).  PDZ domains 
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favor the oligomerization of proteins to allow specific signaling complexes to form (236).  
The PDZ-domain containing protein interacting with PLC-η remains to be identified and 
the functional and physiological significance of such an interaction requires further 
investigation. 
Physiological relevance 
PLC-η2 knockout mice are viable and exhibit no detectable abnormalities (237).  
Transcriptional reporter assays, in-situ hybridization and immunohistochemisry indicated 
that PLC-η2 was highly expressed in the habenula and the retina (237).  Further analysis 
highlighted the previously unappreciated role of PLC-η2 in the development and 
maturation of the retina (237).  Additional studies are required to fully characterize the 
novel function of PLC-η2 in this organ. 
Part III: Auto-regulation of PLC isozymes by their X/Y-linker 
All PLC isoforms are soluble enzymes while their substrate, PtdIns(4,5)P2, is 
membrane-bound.  A required step before substrate hydrolysis is the recruitment of PLCs 
to the plasma membrane.  Different activators specific for each PLC isoform promote the 
translocation of PLCs to the plasma membrane.  However, the molecular details that lead 
to enhanced phospholipase activity after membrane recruitment remain unclear.  Several 
biochemical and structural studies highlight the central role of the X/Y-linker in 
regulating the enzymatic activity of PLC isozymes.  We therefore propose the molecular 
mechanism for activation depends upon the structural and physical properties of the X/Y-
linker intrinsic to each PLC isozyme. 
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Multiple biochemical experiments indicate that disruption of the X/Y-linker of 
PLC isozymes enhances their enzymatic activities.  Specifically, limited proteolysis 
within PLC-δ1 (238), PLC-β2 (239), PLC-γ1 (250, 251), and PLC-ζ (240) targets the 
X/Y-linker and results in PLCs that exhibit higher enzymatic activity.  Along the same 
line, independently expressed polypeptidic chains encompassing the N-terminus to the X-
box and the Y-box to the C-terminus from PLC-β2 (241) or PLC-γ1 (254) reassemble 
together, even in the absence of their respective X/Y-linker, resulting in higher basal 
activity than the holoenzyme.  Moreover, systematic deletion of the X/Y-linker 
dramatically enhances the phospholipase activity of PLC-β2, -β3, -δ1, -ε, -γ1, and -γ2 
both in intact cells and with purified proteins (64, 172, 242).  In addition, the X/Y-linker-
deleted version of several PLC isoforms retain the ability of their respective activators to 
further potentiate phospholipase activity (64, 215), indicating that deletion of the X/Y-
linker does not impair the structural integrity or the signaling capacity of the remainder of 
the protein.  Together, these results indicate that the X/Y-linker mediates auto-inhibition 
of PLC isoforms.  These conclusions are further supported by several high-resolution 
structures that highlight interactions between a portion of the X/Y-linker and the active 
site of PLC-β isozymes (63-65).  Furthermore, the absence of conformational 
rearrangements of the catalytic core of PLC isoforms in the high-resolution structures of 
the PLC-activator complexes (63, 65) is also consistent with the ability of activators to 
potentiate the activity of the ΔX/Y-linker-deleted forms of PLCs. 
A multiple sequence alignment for all 13 human PLC isoforms reveals the two 
regions with the highest (X and Y box) and lowest (X/Y-linker) sequence homology 
among all PLC isoforms.  Strict conservation of residues participating in substrate 
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recognition, ligating the calcium cofactor, and serving as general bases for substrate 
hydrolysis indicates that the mechanism of PtdIns(4,5)P2 hydrolysis is likely to be 
conserved across the PLC family.  In contrast, the X/Y-linker of PLC isozymes is highly 
divergent both in length and composition.  The biochemical and structural studies 
presented above highlight a common inhibitory role of the X/Y-linker of PLC isozymes.  
How is this common function carried out with such divergence in the primary structures 
of the various X/Y-linkers? 
The most noticeable difference in primary structure of the X/Y-linkers of PLC 
isoforms is the length of the X/Y-linker of PLC-γ isozymes compared to the rest of the 
PLC isoforms (Figure 7).  Indeed, the X/Y-linker of PLC-γ isozymes accounts for a third 
of their total masses and at least three times the length of the X/Y-linker of other PLC 
isoforms.  In addition to its larger size, the X/Y-linker of PLC-γ isozymes is the only 
X/Y-linker composed of ordered modular domains.  The X/Y-linkers of other PLC 
isoform are mostly disordered.  To classify the “disordered” X/Y-linkers according to 
their physical properties, we determined the isoelectric point (pI) for each X/Y-linker and 
compared it with the rest of the protein.  PLC isoforms can be divided into two groups 
based on the electrical potential of their X/Y-linker.  The X/Y-linker of PLC-β, -ε, -δ, and 
-η isoforms exhibits a pI more acidic than the whole protein, whereas PLC-ζ is the only 
PLC isoform whose X/Y-linker is more basic than the whole protein.  These differences 
in primary sequence and physical properties likely engender distinct mechanisms of 
activation for the three classes of PLC isoforms defined above based on the intrinsic X/Y-
linker properties (Figure 7). 
PLC isoforms with an acidic X/Y-linker 
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While PLC-δ, -β, -ε, and -η isozymes fall into the category of having a largely 
acidic linker, most of the biochemical and structural knowledge is centered on PLC-δ and 
-β isozymes.  Therefore, these two isoforms will be used as models for the regulated 
activation of PLC-ε and -η isozymes. 
Although both PLC-δ and -β isozymes display a high density of negative charge 
in their X/Y-linker, they diverge structurally.  Specifically, the entire X/Y-linker of PLC-
δ1 (spanning residues 446 – 488) is disordered with no electron density visible in the 
current structures of PLC-δ1 (62).  In contrast, a portion of the X/Y-linker was visible in 
the different structures of PLC-β isozymes (63-65).  In apo-PLC-β2, 22 residues of the 70 
total that comprise the X/Y-linker are ordered (64).  Among the 22 residues, 14 form an 
α-helix that runs perpendicular to the TIM barrel, while the last 8 residues lay on the 
surface of the catalytic cleft and form a small 310 helix that makes direct hydrogen-bond 
contacts with active site residues (64).  The topology and specific interactions with the 
active site are conserved in the complex between PLC-β2 and Rac1 (63).  The PLC-β3 
structure in complex with Gαq also displays residues making direct contacts with the 
active site (65), although differences in resolution likely limit the observation of 
additional residues. 
The modes of activation of PLC-δ and -β isozymes also vary greatly.  PLC-δ1 is 
regulated by PtdIns(4,5)P2 and Ca2+ (85, 93, 243, 244), which bind to the PH and C2 
domains, respectively, to recruit PLC-δ1 at the membrane and enhance its catalytic 
activity (Figure 4).  In addition, basic proteins and polyamines, such as spermine, 
spermidine, and putrescine, also activate PLC-δ1 as their presence decreases the ionic 
strength necessary to reach maximal PLC-δ1 activity (245).  In contrast, PLC-β isozymes 
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have three activators that engage distinct effector sites on PLC-β isozymes.  The Gαq 
subunit binds to the C2 domain and the EF hands (65), the small GTPase Rac binds to the 
PH domain (63), while the binding site for the Gβγ subunits remains undefined (Figure 
5).  
Although the structural nature of the X/Y-linker of PLC-δ and -β differs, deletion 
of the X/Y-linker constitutively activates either PLC isoform (64), indicating that the 
auto-inhibitory function of the X/Y-linker is independent of its structural nature.  For 
example, while PLC-δ1 has only a disordered X/Y-linker, PLC-β isozymes possess a 
small ordered portion that directly occludes the active site.  Importantly, this ordered 
portion sterically blocks the active site even in the presence of different activators, 
strongly indicating that binding of activators is not sufficient to remove auto-inhibition.  
Moreover, superposition of the three structures of PLC-β isozymes highlights no 
conformational changes within the catalytic TIM barrel in the absence or presence of 
activators (63-65), indicating that activators of PLC-β isozymes do not induce allosteric 
changes to elevate the phospholipase activity of PLC-β isozymes.  
Taking into account the structural differences in the X/Y-linker and the modes of 
activation in PLC-δ and -β isozymes, we propose an interfacial mechanism of activation 
for these PLCs driven by electrostatic repulsions between the negatively charged X/Y-
linker and the proximal membranes.  In this model, activators do not induce general 
conformational changes within PLC isoforms, but rather recruit and optimally orient PLC 
isoforms at the plasma membrane to facilitate electrostatic repulsion and removal of the 
X/Y-linker from the active site.  Consistent with this model, removal of monovalent 
acidic phospholipid phosphatidylserine (PS) from the monolayer, decreases the initial 
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rate of PtdIns(4,5)P2 hydrolysis 3-fold for PLC-β1 and -δ1 (246), indicating that the 
presence of negative charges in the inner leaflet of the membrane is essential for maximal 
activities in PLC-β and -δ isozymes.  Consistent with the idea that recruitment at the 
membrane is critical in interfacial activation, Rac-stimulated PLC-β2 activation was 
abolished in detergent-mixed micelles, but not in phospholipid vesicles (64). 
Similar to the PLC-β isozymes, removal of the X/Y-linker does not impair PLC-ε 
activation by upstream regulators.  For example, PLC-εΔX/Y-linker is still activated by 
RhoA and H-Ras (215).  However, additional levels of regulation may be present in PLC-
ε.  Indeed, RhoA engages PLC-ε through a unique insertion within the Y-box (Figure 3), 
which may provide a more direct link between activator binding and release of auto-
inhibition due to spatial constraint.  It would be very informative to dissect the roles of 
the X/Y-linker and the Y-insertion in the mechanisms of RhoA-stimulated PLC-ε 
activation. 
PLC isoform with a basic X/Y-linker 
PLC-ζ isozyme is the only PLC whose X/Y-linker is highly basic, suggesting that 
interfacial activation driven by electrostatic repulsion is unlikely to regulate PLC-ζ.  PSI-
BLAST of human PLC-ζ1 sequence (NP_149114) indicates three isoforms of human 
PLC-ζ1 (Figure 5).  The first isoform of human PLC-ζ1 (NP_149114) is characterized by 
the presence of basic charges and is most similar to the chimpanzee form of PLC-ζ1.  
Isoforms two and three of human PLC-ζ1 isoform (EAW96389.1) and (EAW96390.1), 
respectively, contain a 41-residues insertion, that is highly acidic and reminiscent of the 
high density of negative charges seen in PLC-β, -δ, or -ε isozymes, as well as a basic 
patch.  These two isoforms of human PLC-ζ1 cluster with the macaque form of PLC-ζ1.  
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The other isoforms of PLC-ζ, such as mouse, rat, and chicken, contain an acidic 
insertion, although the length of this insertion is reduced when compared to the human 
PLC-ζ1 (Figure 8).  The functional significance of the differences in the X/Y-linker of 
PLC-ζ orthologs remains unknown. 
To date, no regulatory protein has been shown to directly bind and elevate PLC-ζ 
activity.  In addition, PLC-ζ is the most sensitive PLC to activation by Ca2+ and is 
activated at concentrations of calcium found in resting cells (227), suggesting that PLC-ζ, 
like PLC-δ isozymes, is regulated by calcium.  Conflicting results suggest that the basic 
patches of the X/Y-linker of PLC-ζ may serve as a membrane targeting signal to facilitate 
interaction with the phospholipids (247) or as a nuclear localization signal (230). 
In light of these results, it is tempting to speculate on two possible mechanisms 
for the regulated activation of PLC-ζ isozymes.  On one hand, interfacial activation as 
described for PLC-δ isozymes likely applies to PLC-ζ isozymes harboring the acidic 
insertion.  Alternatively, PLC-ζ isozymes lacking the acidic insertion might be solely 
regulated by proteolytic processing of their X/Y-linker to enhance PLC-ζ catalytic 
activity (240). 
PLC isoform with a structurally ordered X/Y-linker 
PLC-γ isozymes have a unique X/Y-linker composed of modular domains - a split 
PH domain, tandem SH2 domains, and an SH3 domain (Figure 4).  Like other PLC 
isoforms, PLC-γ isozymes are recruited at the plasma membrane by their activators, 
either receptor or cytosolic tyrosine kinases, through engagement of the N-terminal SH2 
(nSH2) domain.  The C-terminal SH2 domain (cSH2) is the critical structural determinant 
in the regulated auto-inhibition of PLC-γ isozymes, as deletion of this domain 
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recapitulates the constitutive activation of PLC-γ isozymes observed with removal of the 
entire X/Y-linker (172).  Although structural data of full-length PLC-γ isozymes or the 
isolated X/Y-linker of PLC-γ isozymes are lacking to understand the structural 
requirements for auto-inhibition of PLC-γ isozymes, it is tempting to speculate that the 
cSH2 domain makes a direct interface with the catalytic domain to repress phospholipase 
activity.  Supporting evidence for this hypothesis lies within the absolute conservation of 
the residues involved in PtdIns(4,5)P2 hydrolysis and the exact superposition of the TIM 
barrels of PLC-δ1 and PLC-β2 (65, 68), suggesting that the catalytic domain does not 
undergo conformational changes.  In addition, these results imply that auto-inhibition is 
mediated by a capping mechanism rather than an intrinsic switch between an inactive and 
active conformation, as seen in protein kinases.  
In addition to a distinct mode of auto-inhibition mediated by a structural domain, 
PLC-γ isozymes also harbor a unique mechanism of activation as they link tyrosine 
phosphorylation with enhanced catalytic activity.  Both of these unique features strongly 
suggest that interfacial activation is unlikely to hold for PLC-γ isozymes.  We have 
recently proposed a mechanism for the phosphorylation-stimulated activation of PLC-γ 
isozymes (172).  In this model, tyrosine kinases phosphorylate PLC-γ isozymes at a 
specific tyrosine, Tyr783 in PLC-γ1 (Tyr759 in PLC-γ2), within the X/Y-linker.  
Phosphorylation of this residue promotes high affinity interactions with the cSH2 
domain, which are required for the phosphorylation-mediated enhancement of 
phospholipase activity (172).  Indeed, substitution of the invariant Argβ5 within the cSH2 
domain that coordinates the phosphate oxygens of the phosphorylated tyrosine and is 
critical for high affinity binding of the phosphorylated tyrosine to the SH2 domain (248, 
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249) eliminates phosphorylation-mediated increases in PLC-γ isozymes activity (172).  In 
addition, increased PLC-γ isozyme activity is associated with a large conformational 
rearrangement of the X/Y-linker with respect to the rest of the protein (172).  Overall, 
PLC-γ isozymes have elaborated on the common mechanism of auto-inhibition observed 
in other PLC isoforms and now couple tyrosine phosphorylation and release of a highly 
complex X/Y-linker. 
Together, these results demonstrate that the auto-inhibitory function of the X/Y-
linker is conserved in all PLC isoforms, but the release of this auto-inhibition is divergent 
among PLC isoforms and is dependent on the primary sequence of the X/Y-linker. 
Auto-inhibition of other lipases 
Regulation of enzymatic activity by auto-inhibition is not a mechanism restricted 
to PLCs.  In fact, multiple phospholipases, like cPLA2 or PLD also possess an active site 
blocked by an intramolecular cap.  The first mammalian lipolytic enzyme to be 
structurally characterized was the human pancreatic lipase (HPL) (250).  HPL is 
functionally organized in two domains.  The N-terminal domain folds into a TIM barrel 
(251) and contains the active site composed of the catalytic triad formed by Ser, Asp, and 
His residues (250).  The active site is buried completely beneath a short helical segment 
within the catalytic domain, or “lid” that is stabilized by van der Waals interactions with 
loops β5 and β9 of the catalytic domain (250), indicating that HPL is basally auto-
inhibited.  The molecular basis for interfacial activation was provided with the structural 
determination of the complex between HPL and lipids (252).  In the activated form of 
HPL, the lid and the β5 loop move away from the active site and folds back onto the core 
of the protein, thereby freeing access to the catalytic triad (252). 
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The superfamily of phospholipase A2 (PLA2) enzymes hydrolyze the sn-2 ester 
bond from phospholipids to release an unsaturated free fatty acid and a lysophospholipid 
(253).  Four main types of PLA2 exist: secreted PLA2 (sPLA2), cytosolic PLA2 (cPLA2), 
calcium-independent PLA2 (iPLA2), and platelet activating factor acetyl 
hydrolyse/oxidized lipid lipoprotein associated PLA2 (LpPLA2) (253).  Structural details 
of cPLA2 indicate that this enzyme is also auto-inhibited by a lid region within a larger 
cap domain (254).  Like HPL, cPLA2 is composed of two domains: an N-terminal C2 
domain that is responsible for calcium-dependent translocation of cPLA2 at the plasma 
membrane, and a C-terminal catalytic α/β hydrolase domain (254).  The highly basic 
180-residue cap domain is structurally folded and may play a role in binding acidic 
substrates.  In contrast, the lid region is folded into a loop that is highly mobile, as 
highlighted by high B-factors for this region (254).  As seen with HPL, displacement of 
the lid region allows PLA2 to undergo interfacial activation whereby its catalytic activity 
is greater in the presence of micelles compared to monomeric substrates (255). 
Another family of lipases whose catalytic activity is controlled by auto-inhibition 
is the phospholipase D (PLD) family.  Mammalian PLD enzymes, PLD1 and PLD2, 
hydrolyze phosphatidylcholine into phosphatidic acid (PA) and choline (256).  PLD 
isozymes contain two catalytic motifs, termed HKD, separated by a variable region in the 
primary sequence (256).  Structural details about the mammalian PLD enzymes are 
lacking, but biochemical data indicate that a PLD1-specific loop between the catalytic 
domains mediates PLD1 auto-inhibition (257).  In addition, the loop-deleted form of 
PLD1 retains the abilities of Arf, PKCα, and Rho GTPases to activate PLD1, suggesting 
that deletion of this loop does not impair the overall folding of PLD1 (257).  The loop 
 46 
region identified in PLD1 is not conserved in PLD2.  Although the mechanisms of PLD 
activation remain unknown, it potentially involves removal of the inhibitory motif to 
undergo interfacial activation. 
Together, these results highlight a common mechanism of auto-inhibition for the 
regulated activity of the lipase family of enzymes.  Indeed, the activity of each lipase 
family is basally repressed by a modular cap or lid that sterically occludes the active site.  
Activation of these lipases required movement of the inhibitory motif away from the 
active site, thereby allowing substrate entry and subsequent hydrolysis.  The auto-
inhibitory mechanisms presented for the lipase family contrast with other auto-inhibitory 
mechanisms seen in tyrosine kinases (258-260) or RhoGEFs (129, 261) in which auto-
inhibition is mediated by conformational changes within the catalytic domains 
incompatible with increase enzymatic activities. 
Concluding remarks 
PLC-γ isozymes are pivotal signaling proteins downstream of growth factor 
receptor activation and immune response signaling.  Among the PLC family, the activity 
of PLC-γ isozymes has been the most directly linked to cellular transformation, reflecting 
the central roles these proteins play in diverse signaling pathways.  It is therefore 
essential to understand the mechanisms that regulate the activity of PLC-γ isozymes.  The 
primary focus of this dissertation was to structurally and biochemically characterize the 
mechanism of PLC-γ isozymes activation.  Structural approaches are discussed in chapter 
two.  Chapter three of this body of work examines the biochemical aspects of the 
regulation of PLC-γ isozymes by their unique X/Y-linker. 
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Figure 1: Phospholipase C-mediated signaling. 
Phospholipase C (PLC) isoforms (red donut) are cytoplasmic enzymes whose activities 
are basally repressed by their X/Y-linker (green donut).  Upon receptor stimulation, by 
either G-protein coupled receptors (GPCR) or receptor tyrosine kinases (RTK) (gold), 
PLC isoforms translocate to the plasma membrane where their substrate, 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) reside.  Upon release of auto-
inhibition, PLC isoforms hydrolyze PtdIns(4,5)P2 into the second messengers 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3).  DAG further 
activates protein kinase C (PKC), while Ins(1,4,5)P3 binds to Ins(1,4,5)P3 receptor (IP3R) 
(gold) to release calcium (Ca2+) from intracellular stores. 
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Figure 2: Mechanism of PtdIns(4,5)P2 hydrolysis 
A Close view of the catalytic site of PLC-δ1 (62) where the soluble head group of the 
substrate is ligated by residues colored in light blue.  The essential calcium cofactor 
(yellow sphere) is ligated by residues colored in magenta.  The residues essential for the 
acid-base mechanism of PtdIns(4,5)P2 are colored in salmon.  In all side chains of the 
above residues, the oxygen atoms are colored in red while the nitrogen atoms are colored 
in blue.  B Mechanism of PtdIns(4,5)P2 hydrolysis proposed by Essen and colleagues 
(62). 
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Figure 3: Catalytic domain of the human PLC isoforms. 
Multiple sequence alignment of the human PLC isoforms spanning the catalytic X and Y 
boxes forming the TIM barrel.  Secondary structure elements based on the known crystal 
structure of PLC-δ1 (62) are indicated above the alignment.  Residues involved in 
substrate recognition (blue), hydrolysis (red), and cofactor ligation (magenta) are also 
indicated.  In addition, the PLC-ε-specific insert within the Y-box is indicated in green. 
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Figure 4: Membrane recruitment of PLC-δ  isoforms. 
The structure of the isolated PH domain of PLC-δ1(blue ribbon) in complex with 
Ins(1,4,5)P3 (shown as stick) (69) indicates that the PH domain of PLC-δ isoforms binds 
phospholipids at the plasma membrane with high affinity.  In addition, the three-
dimensional structure of the rest of the domains of PLC-δ1, consisting of an array of EF 
hands (yellow), a catalytic TIM barrel, and a C2 domain (dark green) was solved 
separately from the highly mobile PH domain (62).  Two calcium-binding domains exist 
within PLC-δ isoforms.  The catalytic domain contains a calcium cofactor essential for 
PtdIns(4,5)P2 hydrolysis (orange sphere).  In addition, the C2 domain also contains two 
calcium ions, shown to favor membrane interaction (69). 
 52 
 
 
Figure 5: Structural requirements for engagement of PLC-β  isoforms by two 
different activators. 
The three-dimensional structure of PLC-β2 solved in isolation (top panel) (pdb entry 
2ZKM (64)) highlights the structural differences of PLC-β isoforms with PLC-δ 
isoforms.  Indeed, the PH domain (blue) of PLC-β2 is packed against the EF hands 
(yellow) and the catalytic TIM barrel (red).  In addition, a small portion of the X/Y-linker 
of PLC-β2 (green) is structurally ordered and positioned above the active site of PLC-β2, 
indicated by the presence of the essential calcium (orange sphere). 
In contrast to PLC-δ1, the PH domain of PLC-β isoforms serves as an effector site of Rac 
GTPases and does not bind phospholipids.  The structural complex between PLC-β2 and 
Rac·GTP (purple) is presented in the lower right panel (pdb entry 2FJU (63)). 
The C2 domain of PLC-β isoforms (dark green) contains a unique extension that allows 
PLC-β isoforms to engage their effector, Gαq (pink).  In the three-dimensional structure 
of the complex between PLC-β3 and Gαq presented in the lower left panel (65), the 
helix-loop-helix extension motif of the C2 domain of PLC-β3 directly engages the 
effector pocket of Gαq composed of switch2 and α3.  In addition, a PLC-β-specific 
insertion between EF hands 3 and 4 contains the determinants for the GTPase activity of 
PLC-β isoforms.
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Figure 6: Regulation of PLC isoforms 
Dendogram of the PLC family highlights common structural elements: PH domain (dark 
blue), EF hands (yellow), catalytic TIM barrel (red), and C2 domain (green).  In addition, 
isozyme-specific regulators are indicated with known (plain arrows) or putative (dashed 
arrows) binding sites.  Green brackets indicate fragments of PLC isoforms with known 
three-dimensional structures.  
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Figure 7: The X/Y-linker of PLC isoforms is highly divergent. 
Multiple sequence alignment of the X/Y-linker of human PLC isoforms highlights the 
divergent structural composition of the X/Y-linker.  PLC-γ isoforms contain the indicated 
structural domains within their X/Y-linker: a split PH domain (cyan), two SH2 domains 
(blue and purple), and an SH3 domain (gold).  In contrast, the X/Y-linker of other PLC 
isoforms is predicted to be disordered based on amino acid composition (64).  The X/Y-
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linker of PLC-ζ is characterized by the presence of basic patches (blue), while the X/Y-
linkers of the remainder PLC isoforms are mostly acidic (red). 
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Figure 8: The X/Y-linker is divergent among PLC-ζ  orthologs 
Multiple sequence alignment of the X/Y-linker of PLC-ζ orthologs highlights the 
divergence within PLC-ζ orthologs.  The X/Y-linker of PLC-ζ can further be divided into 
4 indicated regions.  Regions 1, 3, and 4 are mostly conserved and highly basic (blue), 
while region 2 is unique to specific species of PLC-ζ and contains acidic insertions (red). 
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CHAPTER 2: PURIFICATION AND CRYSTALLIZATION TRIALS OF PLC-γ  
ISOZYMES 
BACKGROUND 
PLC-γ isozymes (-γ1, -γ2) are critical components of growth factor and immune 
response signaling.  Additionally, PLC-γ isozymes metabolize phospholipids to further 
mobilize intracellular calcium and activate PKC, leading to cellular growth and motility.  
Several studies implicate PLC-γ isozymes as a critical component of cellular 
transformation downstream of EGFR/erbB2 activation.  In particular, a report showing 
increased expression of PLC-γ1 in a number of breast cancer tissues indicated that the 
majority of overexpressed PLC-γ1 was phosphorylated in correlation with upregulation 
of both EGFR and human epidermal growth factor 2 (erbB2) (201).  Phosphorylation of 
Tyr775 and Tyr783 in PLC-γ1 leads to its activation (178, 276) while phosphorylation at 
analogous sites (Tyr753 and Tyr759) in PLC-γ2 is similarly activating (199).  Together, 
these findings suggest that the phospholipase activity of PLC-γ isozymes is critical for 
tumorigenesis as the majority of overexpressed PLC-γ isozymes are phosphorylated in 
breast cancer tissues (179).  Additionally, signaling through PLC-γ isozymes downstream 
of VEGFR activation is essential for angiogenesis.  Animals homozygous for the PLC-γ1 
null allele display defects in vasculogenesis and erythropoiesis and die during 
embryogenesis (196).  Angiogenesis is a prerequisite in solid tumor growth as it 
facilitates tumor progression and metastasis (262).  While PLC-γ isozymes occupy a 
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central role in normal and pathological signaling pathways, the molecular events that 
regulate the enzymatic activity of PLC-γ isozymes remain elusive. 
Recent structural and biochemical work suggests that a highly degenerate and 
electronegative X/Y-linker, connecting the two halves of the catalytic TIM barrel (X and 
Y box), basally represses the phospholipase activity of several PLC isoforms (64).  
Unlike other PLCs, the X/Y-linker in PLC-γ isozymes is quite large and contains several 
defined domains (a PH, two SH2, and an SH3).  Several studies suggest that PLC-γ 
isozymes, like other PLC isoforms, are regulated by their X/Y-linker.  Indeed, addition of 
recombinant proteins derived from the X/Y-linker inhibits basal PLC-γ1 catalytic activity 
(278), while deletion of the SH-array within the X/Y-linker increases PLC-γ1 basal 
activity (242).  These findings are consistent with work by Fernald et al. showing that 
PLC-γ1 is activated by proteolytic cleavage between the X and Y boxes (263), and 
suggest that the X/Y-linker of PLC-γ isozymes basally represses its catalytic activity.  
However, aside from these gross deletional and proteolytic studies, there is no clear 
understanding of the structural relationship between the X/Y-linker region in PLC-γ 
isozymes and their activation. 
A complete understanding of the mechanism of PLC-γ isozyme activation 
requires atomic resolution information to complement and support the biochemical 
analysis presented in the following chapter.  To date, no structural information is 
available on full-length PLC-γ isozyme or on the highly elaborated X/Y-linker.  Three-
dimensional structures of the isolated domains composing the X/Y-linker are available as 
follow: split PH domain in isolation (-γ1 pdb entry 2FJL, -γ2 pdb entry 2W2W) and in 
complex with Rac2•GTPγS (-γ2 pdb entry 2W2X), N-terminal SH2 domain in isolation 
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(-γ2 pdb entry 2DXO) and in complex with the kinase domain of FGFR1 (-γ1 pdb entry 
3GQI), C-terminal SH2 domain in isolation (-γ2 pdb entry 2EOB) and in complex with 
phosphorylated peptide (-γ1 pdb entry 2FCI, 2PLD), SH3 domain in isolation (-γ1 pdb 
entry 1YWP, -γ2 pdb entry 2EQI) and in complex with peptide (-γ1 pdb entry 1YWO).  
A primary goal of this thesis was to structurally characterize the auto-inhibited form of 
PLC-γ isozymes. 
Although this aim was not accomplished, below I detail progress towards 
crystallizing auto-inhibited PLC-γ isozymes. 
EXPERIMENTAL PROCEDURES 
Molecular constructs 
The open reading frames of rat PLC-γ1 and human PLC-γ2 were kind gifts from Dr. 
Graham Carpenter (Vanderbilt, TN).  Full-length PLC-γ1 and PLC-γ2 were subcloned 
into a modified pFastBacHT vector, pFBLIC, which incorporates a non-cleavable His6 
tag at the amino terminus of the expressed protein, using a previously published ligation-
independent cloning strategy (264).  A fragment of rat PLC-γ1 (residues 1-1219) lacking 
the degenerate C-terminus was amplified from full-length rat PLC-γ1 by PCR and then 
introduced into a modified pFastBacHT vector, pFBLIC2, as above.  The analogous 
truncation in PLC-γ2 (residues 1 – 1195) was also subcloned into pFBLIC2, which 
incorporates a His6-tag and a tobacco etch virus (TEV) protease site at the amino 
terminus of the expressed protein. 
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Baculovirus expression vector pFBLIC2 containing PLC-γ1 truncated at amino acid 
residue 1219 was used as a template to generate deletion constructs of PLC-γ1 (Δ14, Δ34, 
and Δ64) using the QuickChange site-directed mutagenesis manual (Stratagene).  
The isolated X/Y-linker (residues 485 – 933) and SH-array (residues 548 – 848) were 
PCR-amplified using full-length PLC-γ1 as a template and subcloned into the bacterial 
p15LIC2 expression vector, which incorporates a His6-tag and a TEV site at the N-
terminus of the expressed protein, using the LIC strategy described above.   
PLC-γ1 and PLC-γ2 deletion constructs were generated by standard PCR mutagenesis 
carried out using PLC-γ constructs with the oligonucleotides listed below.  The residues 
removed areindicated in parenthesis.  Also, all primers introduce 12 base pairs encoding a 
flexible GSGS insertion (underlined). 
PLC-γ1Δ30 (759 – 788) 
5’ GGA AGT GGA ATG ATG CCA ACT TTC AAG TGT GCA G 3’ 
5’ ACT TCC ACT TCC CTC GTT GAT GGG GTA GCG C 3’ 
PLC-γ1Δ14 (934 – 947) 
5’ GGT AGT GGT AGT AAG ATC GCC TTG CAG CTC TCC 3’ 
5’ ACT ACC ACT ACC TGC AGT CTG GGC AAC TTC ACG 3’ 
PLC-γ1Δ20 (523 – 542) 
5’ GGT AGT GGT AGT GAG CTG CAC TCG AGC GAG AAG TGG 3’ 
5’ ACT ACC ACT ACC CTC CTC AGA GTA GTA GAT CTT GCT GC 3’ 
PLC-γ2Δ30 (739 – 768) 
5’ GGC AGT GGT AGT ATG CCT CAG AGA ACC GTG AAA GCT CTG TAT GAC 
TAC AAA GCC 3’ 
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5’ ACT ACC ATC GCC CTC GGG GGT CAC GGG GTA GCG CAG TCT CAT CTT 
TCG 3’ 
All constructs were verified by automated DNA sequencing. 
Protein expression and purification 
Modified pFastBac vectors encoding various mutant forms of PLC-γ1 described above 
were transformed into DH10Bac cells (Invitrogen) to produce bacmid DNA, which was 
subsequently used to generate baculovirus in Sf9 cells according to the manufacturer’s 
protocol (Invitrogen Bac-to-Bac manual).  High-Five insect cells at a density of 1.5 – 2.0 
X 106 cells/ml were infected with baculovirus encoding individual PLC-γ1 constructs at 
an MOI of ~1.0 for 48 hrs at 27°C. 
Recombinant PLC-γ1 proteins expressed in the pFBLIC2 vector were purified as follow.  
Cells were harvested at 3000 rpm and resuspended in 150 ml of buffer NA (20 mM Tris 
(pH 8), 300 mM NaCl, 10 mM Imidazole, 10 % [v/v] glycerol) with 15 mM β-
mercaptoethanol (βMe) and four EDTA-free complete protease inhibitor tablets (Roche 
Applied Science).  Cells were lysed using an EmulsiFlex C5 homogenizer (Avestin) and 
spun at 60,000 rpm for 1h at 4°C.  The clarified supernatant was loaded onto a 5 ml 
HisTrap FF crude column (GE Healthcare) charged with Ni2+.  Purification steps 
included a 15-column volume (CV) buffer NA wash and a 12 CV wash with 5% NB 
buffer (NA buffer containing 1 M imidazole).  Recombinant PLC-γ1 proteins were eluted 
with 7 CV of 40% NB buffer.  Eluted PLC-γ1 proteins were dialyzed overnight against 
buffer N2 (20 mM Tris (pH 8), 300 mM NaCl, 10% [v/v] glycerol) in the presence of the 
TEV protease and 2 mM DTT to remove the His6 tag from the PLC-γ1 proteins.  The 
cleaved proteins were then subjected to a second passage over a Ni2+ charged metal 
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chelate column.  Fractions containing the purified proteins were diluted in QA buffer (20 
mM Tris (pH 8), 50 mM NaCl, 10% [v/v] glycerol, 2 mM DTT), subsequently loaded 
onto a 1 ml SourceQ anion exchange column (GE Healthcare), and eluted with a linear 
gradient of 0% - 50% buffer QB (QA + 1 M NaCl) over 20 CV.  Fractions containing the 
purified PLC-γ1 proteins were then loaded onto a HiLoad 16/70 Superdex200 column 
(GE Healthcare) to ensure samples eluted a monodispersed species of correct molecular 
weight.  Fractions containing purified PLC-γ1 proteins were pooled and concentrated 
using a 30,000 MWCO Vivaspin 20 centrifugal filtering device (Vivascience).  Protein 
concentrations were determined using Beer’s law with extinction coefficients calculated 
using the ProtParam tool (ExPaSy Molecular Biology Server (265)), analyzed by SDS-
PAGE to confirm concentration and ensure purity, and subsequently stored at -80°C after 
flash freezing in liquid nitrogen. 
PLC-γ1 recombinant proteins expressing a non-cleavable His6-tag (pFBLIC vector) were 
purified as described above with minor modifications.  Proteins were eluted from the first 
metal affinity column and dialyzed for four 4 hours against buffer N2 and overnight 
against buffer QA.  The proteins were then applied to a 1 ml SourceQ column, and the rest 
of the purification scheme followed the above description. 
Recombinant isolated X/Y-linker and SH-array of PLC-γ1 and PLC-γ2 expressed in the 
p15LIC2 vector were expressed in the BL21 (DE3) Escherichia coli strain.  Cells were 
grown at 37°C in LB media containing 0.1 mg/ml ampicillin until an A600 of ~0.7, 
induced with 50 µM isopropyl β-D-thiogalactopyranoside (IPTG), and grown at 18°C for 
16 – 18 h.  The PLC-γ1 fragments were purified by sequential metal affinity 
chromatography, TEV protease treatment overnight, followed by a second metal affinity 
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column and a size-exclusion chromatography using a HiLoad Superdex75 16/70 column 
(GE Healthcare).  All proteins were concentrated using a 10,000 MWCO Vivaspin 20 
(Vivascience), flash-frozen in liquid nitrogen, and stored at -80°C. 
Size-exclusion chromatography – Multi angle light scattering (SEC-MALS) 
Light scattering measurements were made with a Wyatt DAWN EOS light scattering 
instrument (Wyatt Optilab refractometer, and Wyatt dynamic light scattering module) 
coupled to an AKTA FPLC (GE Healthcare).  PLC-γ1 proteins (250 µl at ~4.0 mg/mL) 
were loaded onto a Superdex200 10/300 GL column (GE Healthcare) pre-equilibrated 
with 20 mM Tris (pH 8.0), and 200 mM NaCl.  Data collection and analyses were 
performed with ASTRA software version 4.90.08 (Wyatt Technologies). 
Crystal screens 
Initial crystallization screens were carried out using sitting drop vapor diffusion 
technique.  Briefly, drops formed by combining equal volumes of protein solution and 
reservoir solution were placed in vapor equilibration with a liquid reservoir.  Commercial 
sparse matrix screens used for the reservoir solution were The Classics Suite (Qiagen), 
The Classics Lite (Qiagen), The AmSO4 Suite (Qiagen), The PEGs Suite (Qiagen), 
Crystal Screen (Hampton Research), Crystal Screen 2 (Hampton Research), Index 
(Hampton Research), and SaltRx (Hampton Research).  Promising conditions containing 
crystal spherulites, or non-amorphous precipitates were improved through optimization of 
different conditions known to affect the crystallization process, such as pH, protein 
concentration, temperature, and protein-to-precipitant ratio. 
 64 
Limited proteolysis 
PLC-γ1 proteins and proteases were mixed in 1:100 (w/w) protease:protein ratio in 
protease-specific buffer at room temperature.  Aliquots of each reaction were removed at 
specific time points, boiled to inactivate the protease, and analyzed by SDS-PAGE. 
Complex formation between PLC-γ2 and RacGTPase 
PLC-γ2 (30 µM) was incubated on ice for 30 minutes with a three-fold molar excess of 
Rac2 pre-loaded with either GDP or GTPγS in buffer containing 20 mM Tris (pH 7.5), 
150 mM NaCl, 5% glycerol, 1 mM DTT, and 10 mM MgCl2.  Proteins were then 
separated using an analytical Superdex200 (GE Healthcare) pre-equilibrated with the 
above buffer and elution fractions were then analyzed by SDS-PAGE. 
RESULTS 
N and C-terminal modifications do not favor crystallization of PLC-γ  isozymes. 
Full-length PLC-γ1 and -γ2 expressing a non-cleavable N-terminal His6-tag were 
purified to homogeneity from baculovirus-infected insect cells using sequential affinity, 
anion-exchange, and size-exclusion chromatography.  The highly pure PLC-γ1 and -γ2 
proteins were used to carry out initial crystallization screens using sitting drop vapor 
diffusion techniques.  In addition to sparse matrix screens, precipitant type and pH were 
varied in a more systematic approach to favor crystallization of both PLC-γ1 and -γ2.  
Two temperatures (18° and 4°C) and a range of protein concentrations (13.25 to 30 
mg/ml) were used in the different crystallization trials.  However, none of the tested 
conditions yielded any appreciable crystalline form of either PLC-γ1 or -γ2.  Later SEC-
MALS analysis of (His)6-PLC-γ1 indicated that in solution, this protein exists as a 
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monomer-dimer equilibrium (Figure 16), suggesting that the presence of higher order 
oligomers might have prevented crystal formation of this protein. 
The presence of disordered regions typically inhibits protein crystallization.  We 
therefore used ClustalX (266) to produce a multiple sequence alignment from various 
PLC-γ orthologs to identify regions of very low sequence conservation.  The overall 
sequence conservation of PLC-γ isozymes drops after the C2 domain, indicating that the 
C-termini of PLC-γ isozymes are degenerate.  We therefore generated truncation 
constructs of PLC-γ isozymes that remove the C-terminus.  This truncation construct is 
analogous to the PLC-β2 construct that yields high-resolution diffraction data (64) and 
retains all structural domains of PLC-γ isozymes.  In addition, a novel baculovirus 
expression vector that encodes a cleavable N-terminal (His)6-tag was utillized to remove 
additional N-terminal sequences. 
The resulting PLC-γ constructs, PLC-γ1 1-1219 and PLC-γ2 1-1195, were 
expressed in baculovirus-infected insect cells and purified to homogeneity.  Later SEC-
MALS analysis of the PLC-γ1 truncated form indicated that this species is monomeric 
and monodisperse (Figure 15), suggesting that this protein should be highly amenable to 
crystallography.  Commercial and home-made crystallization screens with PLC-γ1 1-
1219 and PLC-γ2 1-1195 were carried out at both 18°C and 4°C with protein 
concentrations of 20 and 10 mg/ml, respectively.  Overall, 400 – 600 conditions were 
tested using these two proteins.  However, none of the tested conditions yielded 
crystalline precipitants. 
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Limited proteolysis identified loop regions within PLC-γ  isozymes. 
In addition to degenerate N- and C-termini, the presence of loop regions often 
inhibits protein crystallization as these regions correlate with large B-factors and 
uncertain electron density, and display conformational flexibility.  We used limited 
proteolysis with four different proteases to identify surface-exposed loop regions of PLC-
γ1.  Analogous cut sites were identified in PLC-γ1 with Trypsin, Lys-C, and Asp-N 
proteolysis.  In contrast, V8-mediated PLC-γ1 proteolysis was instantaneous, likely due 
to the inadequate ratio of protein:protease for this particular protease, and therefore 
prevented any subsequent digestive pattern analysis.  Overall, PLC-γ1 proteolysis was 
complete after two hours with all four proteases used.  Using N-terminal Edman 
sequencing, we identified two major proteolysis-sensitive regions: the first one is located 
between the C-terminal half of the split PH (csPH) domain and the Y box (residues 934 – 
947), and the second one is located between the C-terminal SH2 (cSH2) domain and the 
SH3 domain (residues 749 to 788) (Figure 9).  We also used multiple sequence alignment 
to identify a region of low conservation between the N-terminal half of the split PH 
(nsPH) domain and the N-terminal SH2 (nSH2) domain (residues 523 – 542). 
Using proteolytic and sequencing information, we generated three PLC-γ1 
deletion constructs to remove flexible loops and ultimately favor crystallization.  PLC-
γ1Δ14 deletes residues 934 to 947 between the csPH domain and the Y box; PLC-γ1Δ34 
was generated using PLC-γ1Δ14 as a template with deletion of an additional 20 residues 
(523 – 542) between the nsPH domain and the nSH2 domain; PLC-γ1Δ64 was generated 
using PLC-γ1Δ34 as a template with deletion of 30 additional residues (749 – 788) 
between the cSH2 and the SH3 domain.  All three PLC-γ1 proteins were purified to 
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homogeneity from baculovirus-infected insect cells.  Limited proteolysis was also 
performed using Lys-C protease on these proteins to insure their stabilities.  While PLC-
γ1Δ14 and PLC-γ1Δ34 were still protease-sensitive as the proteolytic region between the 
cSH2 and the SH3 domain was present (Figure 10), PLC-γ1Δ64 was highly susceptible to 
proteolysis and therefore unstable (Figure 11). 
Nonetheless, the three deletion forms of PLC-γ1 presented above were used to 
screen numerous crystallization conditions.  As stated previously, concentration (18 to 45 
mg/ml) and temperature (4°C and 18°C) were varied for each of the PLC-γ1 constructs.  
None of the screened conditions formed any protein crystals.  In light of these results, we 
used an in situ proteolysis strategy where the protease is added directly to the crystal drop 
to form protein crystals suitable for structure determination.  Using PLC-γ1 1-1219 as the 
starting material, as it is monomeric and monodisperse, we added trypsin in a 
protease:protein ratio of 1:500 and screened several conditions.  To date, no crystalline 
precipitant has been observed.  
Full-length PLC-γ2 does not form a complex with GTPγS loaded Rac2 on size-
exclusion chromatography. 
Another technique to induce protein crystallization is the addition of a binding 
partner, which forms a tight complex with the protein of interest and may favor crystal 
formation.  At the time of this study, Rac2 was just discovered as a novel activator for 
PLC-γ2, but not PLC-γ1 (193).  With the goal of crystallizing a complex between Rac2 
and PLC-γ2, we used size-exclusion chromatography to attempt to complex GTPγS-
loaded Rac2 and PLC-γ2 (Figure 12).  In our hands, we did not detect any complex 
formation between the two proteins.  We did not further pursue this crystallization target.  
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Recent biochemical and structural work, not known at the time of the study, defined the 
split PH domain of PLC-γ2 as the binding interface with Rac (191, 194).  Furthermore, 
the low µM affinity measured between the two proteins using ITC is consistent with our 
inability to complex Rac2•GTPγS and PLC-γ2 over a gel filtration column. 
The isolated X/Y-linker of PLC-γ  isozymes is monomeric and monodisperse in solution. 
To date, full-length PLC-γ1 or -γ2 remains refractory to crystallization.  A smaller 
fragment of PLC-γ isozymes, the isolated X/Y-linker, is an attractive target as it contains 
the PLC-γ-specific domains and regulates the enzymatic activity of PLC-γ isozymes.  In 
addition to its smaller size, the X/Y-linker of PLC-γ isozymes is amenable to a bacterial 
expression system while full-length PLC-γ isozymes requires a baculovirus expression 
system.  We therefore purified to homogeneity the X/Y-linker of PLC-γ1 and screened 
numerous crystallization conditions.  Deletions analogous to the ones presented above 
were introduced in the X/Y-linker of PLC-γ1.  These deletion forms of the X/Y-linker of 
PLC-γ1 (PLC-γ1 X/Y-linkerΔ30 and PLC-γ1 X/Y-linkerΔ50) were purified to 
homogeneity and subsequently screened using an in-house high-throughput system 
(Figure 13).  However, none of the tested conditions yielded any protein crystals. 
Although the X/Y-linker of PLC-γ1 is highly soluble, the X/Y-linker of PLC-γ2, 
is mostly insoluble and therefore requires expression in insect cells.  Analogous to the 
X/Y-linker of PLC-γ1, we generated a deletion form of the X/Y-linker of PLC-γ2 (PLC-
γ2 X/Y-linkerΔ30) and purified it to homogeneity from baculovirus-infected insect cells. 
To gain insight into the stability of the isolated X/Y-linker, we subjected PLC-γ1 
X/Y-linker and PLC-γ1 X/Y-linkerΔ50 to limited proteolysis (Figure 13).  Surprisingly, 
the digestive pattern for both proteins was identical, suggesting that the X/Y-linker 
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behaves differently from full-length PLC-γ1.  The fragmentation of the X/Y-linker of 
PLC-γ1 from Lys-C digestion likely reflects a proteolytic region that might be protected 
from solvent-exposure in the full-length protein.  It is possible that this protected surface 
of the X/Y-linker represents the contact points with the core domains of PLC-γ1, 
particularly with the catalytic TIM barrel. 
The SH-array as an alternative crystallographic target. 
The minimal unit participating in auto-inhibition of PLC-γ isozymes is the SH-
array, composed of tandem SH2 domains followed by a SH3 domain.  We therefore 
purified the wild-type form of the SH-array of PLC-γ1 and a deleted form of the SH-array 
of PLC-γ1 (PLC-γ1 SH-arrayΔ30) to homogeneity and subjected both proteins to 
crystallization trials (Figure 14).  To date, none of the conditions screened yielded any 
crystalline precipitant. 
DISCUSSION 
PLC-γ isozymes are pivotal enzymes downstream of growth factor signaling, 
whose activation leads to processes critical for tumorigenesis, such as angiogenesis and 
cell motility.  As signaling nodes, PLC-γ isozymes represent an attractive drug target to 
manipulate growth factor signaling.  Structural information would greatly enhance our 
ability to develop potent modulators of the enzymatic activity of PLC-γ isozymes.  One 
aim of this thesis was to crystallize PLC-γ isozymes to gain atomic resolution details 
about the mechanism of activation of these enzymes. 
One major factor influencing protein crystallization is the purity of the protein.  
We successfully purified to homogeneity both PLC-γ1 and PLC-γ2 from baculovirus-
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infected insect cells.  Although a large chemical space was probed and factors known to 
influence lattice formation, such as temperature and protein concentration, were varied, 
none of the tested conditions yielded any crystalline precipitant.  Light scattering analysis 
indicated that full-length PLC-γ1 exists mostly as a monomer with the presence of small 
dimer aggregate in solution (Figure 16).  It is possible that the presence of higher order 
aggregates might have prevented crystal formation for these proteins.   
Another factor greatly influencing protein crystal formation is the presence of 
disordered regions whose structural flexibilities often inhibit crystal lattice formation.  
Combinations of low sequence conservation and limited proteolysis were used to 
generate additional crystallographic targets of PLC-γ isozymes potentially more 
amenable to crystallization (Figures 9, 10, and 11).  However, none of the novel 
constructs of PLC-γ isozymes yielded any crystalline precipitants in the large array of 
conditions tested.  Thus, additional techniques must be employed in future studies to 
crystallized PLC-γ isozymes. 
Crystallization can be promoted by changing the surface properties of the protein 
to reduce the conformational entropy of surface residues.  To this end, reductive 
methylation of surface-exposed lysines could be used as an alternative approach to favor 
crystallization of PLC-γ isozymes (267).  Alternatively, protein crystallization is often 
facilitated by the addition of ligand or binding partner (Figure 12), which lowers the 
intrinsic heterogeneity of the protein.  For example, PLC-δ1 was crystallized in the 
presence of its substrate’s soluble head group, Ins(1,4,5)P3 (62).  This avenue should be 
explored to facilitate crystallization of PLC-γ isozymes.  
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Although we utilized smaller fragments of PLC-γ isozymes, the X/Y-linker and 
the SH-array, as alternative crystallographic targets to the full-length PLC-γ isozymes, 
none of tested conditions yield crystalline precipitates.  It is possible that addition of 
small molecules, including physiologically-relevant phosphorylated peptides, might favor 
protein crystal formation. 
Alternatively, techniques outside of X-ray crystallography could be used to gain 
structural information on PLC-γ isozymes.  Specifically, homology modeling of the core 
domains of PLC-γ isozymes could be done based on the structures of PLC-β isozymes 
(63-65) and PLC-δ1 (62).  In addition, individual structural information of the domains 
composing the X/Y-linker could also be used to dock these domains together and 
recompose the X/Y-linker.  However, it would be critical to perform an evolutionary 
analysis to identify the primordial unit of the X/Y-linker of PLC-γ isozymes before 
docking the different domains. 
Another technique to obtain structural information on full-length PLC-γ isozymes 
is small angle X-ray scattering (SAXS) (268).  Although the resolution is much lower 
than X-ray crystallography, SAXS does not require crystalline proteins and the sample 
preparation is minimal.  SAXS can be used to model a large macromolecule complex 
whose overall structure is unknown but where the structures of individual components are 
available.  While we have collected SAXS data of the truncated form of PLC-γ1 at the C2 
domain, to date, the data remained to be fully analyzed. 
An alternative in-solution technique that could be used to obtain structural 
information about PLC-γ isozymes is nuclear magnetic resonance spectroscopy (NMR) 
(269).  Only the SH-array and the X/Y-linker of PLC-γ isozymes are amenable to NMR 
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as their molecular weights are lower than the upper size limitation of NMR (<50 kDa), 
and both proteins are soluble and stable at high concentrations, both desired features for 
NMR.  As explored previously, several deletions or ligand additions could be used to 
facilitate NMR.
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Figure 9: Limited proteolysis of PLC-γ1 reveals two major protease-sensitive sites. 
PLC-γ1 and Asp-N protease were mixed at 1:100 protease:protein ratio in protease-
specific buffer.  Aliquot of the reactions were taken at the indicated time and 
subsequently ran on SDS-PAGE.  The PLC-γ1 fragments and their respective molecular 
weights resulting from Asp-N proteolysis are indicated to the right of the gel.  The 
proteolytic sites are indicated with a black arrow. 
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Figure 10: PLC-γ1Δ14 and PLC-γ1Δ34 remain protease-sensitive. 
Wild-type or the indicated forms of PLC-γ1, described in the upper panel, were subjected 
to limited proteolysis with Lys-C protease.  At the indicated time point, aliquot of the 
reaction was taken and subsequently ran on SDS-PAGE (lower panel).  The PLC-γ1 
fragments are indicated (right of the gel) as well as the remainder proteolytic site (black 
arrow). 
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Figure 11: Deletion of the protease-sensitive regions destabilizes PLC-γ1. 
Wild-type or the indicated forms of PLC-γ1 (upper panel) were subjected to limited 
proteolysis with Lys-C protease.  At the indicated time, aliquot of the reaction was taken 
and ran on SDS-PAGE (lower panel).   
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Figure 12: PLC-γ2 and the small GTPase Rac2 do not complex on size-exclusion 
chromatography. 
PLC-γ2 (50 µM) and a three-fold excess of the indicated nucleotide-form of Rac2 were 
mixed on ice for 30 min before loading onto an analytical Superdex200 column (GE 
Healthcare).  Elution fractions were analyzed by SDS-PAGE. 
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Figure 13: The isolated X/Y-linker of PLC-γ1 is protease-sensitive. 
Wild-type and the indicated form of the X/Y-linker of PLC-γ1 were purified to 
homogeneity (upper panel) and subjected to limited proteolysis with Lys-C (lower panel).  
Green brackets indicate the known three-dimensional structures of the individual domains 
of the X/Y-linker, as shown above the diagram.  Specifically, the split PH domain of 
PLC-γ1 is shown in cyan (pdb entry 2FJL), the tandem SH2 domains of PLC-γ1 is shown 
in blue and purple (pdb entry 3GQI), and the SH3 domain of PLC-γ1 is shown in beige 
(pdb entry 1YWP). 
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Figure 14: The SH-array is a tractable crystallographic target. 
Wild-type and the indicated form of the SH-array of PLC-γ1 (upper panel) were purified 
to homogeneity (lower panel).  Green brackets indicate the known three-dimensional 
structures of the SH-array. 
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CHAPTER 3: MECHANISM OF PHOSPHORYLATION-INDUCED 
ACTIVATION OF PLC-γ  ISOZYMES  
BACKGROUND 
Phospholipase C (PLC) isozymes hydrolyze phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) into the second messengers diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3) (60).  DAG and IP3 subsequently activate protein kinase 
C (PKC) isozymes and liberate intracellular calcium stores, respectively, thereby 
initiating and propagating numerous cellular events including: fertilization, proliferation, 
differentiation, and chemotaxis (270). 
The mammalian PLC family contains thirteen isozymes subdivided into six 
subtypes (-β, -δ, -γ, -ε, -η, and -ζ) based on structural homology (60).  The highest 
sequence similarity among PLCs lies within the catalytic triose phosphate isomerase 
(TIM) barrel comprised of two halves (X and Y boxes) separated by a highly degenerate 
X/Y-linker.  The active site is essentially invariant in PLC enzymes and ligates a calcium 
ion cofactor necessary for deprotonation of the PtdIns(4,5)P2 substrate and stabilization 
of the transition state (62).   
Using structural and biochemical information, we recently showed that the X/Y-
linker in PLC-β, -δ, and -ε isozymes mediates auto-inhibition of phospholipase activity 
(64).  The X/Y-linker of these PLCs is highly negatively charged, mostly disordered, and 
prevents PtdIns(4,5)P2 access to the active site by a combination of steric exclusion and 
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electrostatic repulsion of negatively charged membranes.  Consequently, we proposed a 
general mechanism of interfacial activation of these isozymes in which any upstream 
input that preferentially orients the active site toward PtdIns(4,5)P2-containing 
membranes would remove the X/Y-linker to allow access of substrate for hydrolysis (64). 
In contrast to all other PLCs, the PLC-γ isozymes (-γ1, -γ2) possess highly 
elaborated X/Y-linkers containing multiple domains: a split PH domain, two SH2 
domains, and an SH3 domain (Figure 15A).  Nevertheless, like other PLC isoforms (238, 
239), deletion (242) or proteolysis (250, 251, 254) of the X/Y-linker modestly (2-5 fold) 
enhanced phospholipase activity of PLC-γ1.  Similarly, fragments of PLC-β2 (241) or -γ1 
(254) lacking the X/Y-linker associated after overexpression to produce catalytically 
competent enzymes with elevated phospholipase activity.  Therefore, although the 
composition of the X/Y-linkers of PLC-γ isozymes dramatically differs from other PLCs, 
these X/Y-linkers may also function to maintain low basal phospholipase activity.   
PLC-γ isozymes are directly activated by numerous receptor tyrosine kinases 
(RTKs) and cytosolic tyrosine kinases (270).  This activation typically involves two 
steps: i) membrane-recruitment of the PLC-γ isozymes through binding of the N-terminal 
SH2 domain (nSH2) within the X/Y-linker to phosphorylated tyrosines within RTKs or 
adaptor proteins, and ii) phosphorylation of the PLC-γ isozymes.  While PLC-γ1 can be 
phosphorylated at five tyrosines (472, 771, 775, 783, and 1254) (177, 178, 276), only 
phosphorylation of Tyr775 and Tyr783 is critical for phospholipase activation since 
substitution at either site (or analogous substitutions within PLC-γ2 (199, 286)) 
compromises activation in a variety of signaling cascades (178, 287).   
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Although it has been recognized for twenty years that tyrosine phosphorylation of 
PLC-γ isozymes enhances their phospholipase activity, the molecular details linking 
phosphorylation to activation remain poorly defined.  In this report, we used highly 
purified proteins and robust in vitro assays to discover that PLC-γ isozymes have 
modified the common mechanism of interfacial activation present in most PLCs to couple 
phosphorylation of a highly-elaborated X/Y-linker with release of auto-inhibition and 
consequential activation. 
EXPERIMENTAL PROCEDURES 
Molecular constructs 
Standard PCR-mediated mutagenesis (Stratagene; QuickChange site-directed 
mutagenesis manual) was used to introduce deletions or substitutions into the open 
reading frames of rat PLC-γ1 and human PLC-γ2 [kind gifts from Dr. Graham Carpenter 
(Vanderbilt, TN)]. 
Full-length PLC-γ1 was subcloned into a modified pFastBacHT vector, pFBLIC, which 
incorporates a non-cleavable His6 tag at the amino terminus of the expressed protein, 
using a previously published ligation-independent cloning strategy (264).  This 
baculovirus expression vector, PLC-γ1 pFBLIC, was used to generate vectors for PLC-
γ1Δ15 and PLC-γ1cSH2* (R694A/R696A/K711A/K713A).  A fragment of rat PLC-γ1 
(residues 1-1219) lacking the degenerate C-terminus was PCR-amplified from full-length 
rat PLC-γ1 and then introduced into a modified pFastBacHT vector (pFBLIC2) as 
described above.  The baculovirus expression vector, pFBLIC2, which incorporates a 
His6-tag and a tobacco etch virus (TEV) protease site at the amino terminus of the 
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expressed protein, was used to generate vectors for deletion constructs of PLC-γ1 (ΔsPH, 
ΔnSH2, and ΔSH3), as well as single and double point mutants of PLC-γ1 (Y771F, 
Y775F, Y783F, Y775E/Y783E, Y771F/Y778F, Y775F/Y783F, nSH2*(R586A)) in the 
context of truncated PLC-γ1 using the QuickChange site-directed mutagenesis manual 
(Stratagene).  Certain PLC-γ1 constructs, for which protein expression was refractory in 
insect cells, were subcloned into a modified pPICZ vector for expression in Pichia 
pastoris using the above strategy.  The Pichia pastoris expression vector, pPICZ-LIC, 
which incorporates a His6 tag followed by a TEV protease site at the N-terminus of the 
expressed protein, was used to generate vectors for the following PLC-γ1 deletion 
constructs: ΔX/Y-linker, ΔcSH2, and Δ10, in the context of truncated PLC-γ1.  Full-
length rat PLC-γ1 and human PLC-γ2 were also subcloned into a modified pcDNA3.1 
vector as above.  The mammalian expression vector, pcHA-LIC, which incorporates a 
HA-tag at the N-terminus of the expressed protein, was used to generate deletion 
constructs of PLC-γ1 (ΔX/Y-linker, ΔsPH, ΔSH, ΔnSH2, ΔcSH2, ΔSH3) and PLC-γ2 
(ΔX/Y-linker, Δ10, ΔsPH, ΔYY). 
The isolated nSH2 domain (residues 546 – 662), cSH2 domain (residues 664 – 758), and 
X/Y-linker (residues 485 – 933) were PCR-amplified using full-length PLC-γ1 as a 
template and subcloned into the bacterial p15LIC2 expression vector using the strategy 
described above.  The isolated split PH domain (residues 485 – 530 and 870 – 933) was 
PCR-amplified from PLC-γ1ΔSH and subcloned into p15LIC2 as described above.  
The kinase domain of FGFR2 (residues 458 – 778), FGFR2K, was PCR amplified from 
the full-length FGFR2 (provided by Channing Der, UNC-CH (271)) and subcloned into a 
modified pET15b vector (Novagen).  The constitutively active mutation (E565A) (260) 
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was generated using PCR-mediated mutagenesis (Stratagene; QuickChange site-directed 
mutagenesis manual).  All mutant genes were verified by automated DNA sequencing of 
the entire open reading frame. 
Construction of deletions within PLC-γ1 and -γ2 
Mutagenic primers used for PLC-γ1 and -γ2 deletion constructs included 12 base 
pairs encoding a Gly-Ser-Gly-Ser insertion spanning the deleted regions.   Standard PCR 
mutagenesis was carried out using PLC-γ constructs with the oligonucleotides listed 
below and designed to remove the desired residues indicated in parenthesis.  The 12 base 
pairs encoding the flexible GSGS insertion are underlined. 
PLC-γ1ΔX/Y-linker (471 – 938) 
5’ GGC AGT GGC AGT GAG GGG AAG ATG ATG GAG AGG AGG 3’ 
5’ ACT GCC ACT GCC ACT GCC CTC AGC CAG CTT CTT ATG C 3’ 
PLC-γ1Δsplit PH (486 – 542 and 871 – 947) 
5’ GGT AGT GGT AGT GAG CTG CAC TCG AGC GAG AAG TGC 3’ 
5’ ACT ACC ACT ACC GTC ATT CTC AGA GTA CAT CAC AGA GG 3’ 
5’ GGT AGT GGT AGT AAG ATC GCC TTG GAG CTC TCC 3’ 
5’ ACT ACC ACT ACC GTC CCC CAG TGG GCT GTT CTC ATC 3’ 
PLC-γ1ΔSH (531 – 869) 
5’ GGT AGT GGT AGT GAC TTG CTG CGA GGG GTC TTA GAT G 3’ 
5’ ACT ACC ACT ACC GTC ATT CTC AGA GTA CAT CAC AGA GG 3’ 
PLC-γ1ΔnSH2 (531 – 665) 
5’ GGT AGT GGT AGT AAA GAG TGG TAC CAC GCA AGC 3’ 
5’ ACT ACC ACT ACC GTC ATT CTC AGA GTA CAT CAC AGA GG 3’ 
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PLC-γ1ΔcSH2 (668 – 784) 
5’ GGT AGT GGT AGT GAG GCC AAC CCT ATG CCA ACT TTC AAG 3’ 
5’ ACT ACC ACT ACC CTC TTT GCT CTC ATG GGC ATT CGT CTG 3’ 
PLC-γ1ΔSH3 (786 – 869) 
5’ GGT AGT GGT AGT GAC TTG CTG CGA GGG GTC TTA GAT G 3’ 
5’ ACT ACC ACT ACC CTC CAC ATA GAA ACC AGG 3’ 
PLC-γ1Δ10 (746 – 755) 
5’ GGT AGT GGT AGT ATC AAC GAG GAG GCG CTG GAG AAG ATT GGG 3’ 
5’ ACT ACC ACT ACC GGG ATG CTT CTC ATA GTA GCT GAT GAG GTC GAC 
3’ 
PLC-γ1Δ15 (759 – 772) 
5’ GGA TCA GGA TCA GCA CTG TAT GAG GGC CGC AAC CCT GGT TTC TAT 
GTG GAG GCC 3’ 
5’ TGA TCC TGA TCC CTC GTT GAT GGG GTA GCG CAG TTT CAT TTT GCG 3’ 
PLC-γ1Δ30 (759 – 788) 
5’ GGA AGT GGA ATG ATG CCA ACT TTC AAG TGT GCA G 3’ 
5’ ACT TCC ACT TCC CTC GTT GAT GGG GTA GCG C 3’ 
PLC-γ2ΔX/Y-linker (464 – 920) 
5’ GGC AGT GGA AGT GAG AAG AAC CAG TCC ATC GCC ATC GAG CTC TCT 
GAC CTG G 3’ 
5’ ACT TCC ACT GCC ATC GCC TCG GGG GCC CAG CTT CTT ATG CTT GAT 
GAT GAT CTT CTC CCG 3’ 
PLC-γ2Δsplit PH (464 – 515 and 842 – 920) 
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5’ GGC AGT GGA AGT GAA GTG CCC CAG GAT ATA CCC CCT ACA GAA  
C 3’ 
5’ ACT TCC ACT GCC ATC GCC TCG GGG GCC CAG CTT CTT ATG CTT GAT 
GAT GAT CTT CTC CCG 3’ 
5’ GGC AGT GGA AGT GAG AAG AAC CAG TCC ATC GCC ATC GAG CTC TCT 
GAC CTG G 3’ 
5’ ACT TCC ACT GCC TTC AAT AAT CTG CTT TTC TAG CTC CTC GAA GTC 
TGC 3’ 
PLC-γ2Δ10 (725 – 734) 
5’ GGT AGT GGT AGT GTG ACC CCC GAG CTC CTG GAG CGC TAC AAT ATG 
3’ 
5’ ACT ACC ACT ACC TGA ATG CTT CTC GTA GTA ACT GAC GAG CTC 3’ 
PLC-γ2ΔYY (751 – 768) 
5’ GGC AGT GGT AGT ATG CCT CAG AGA ACC GTG AAA GCT CTG TAT GAC 
TAC AAA GCC 3’ 
5’ ACT ACC ACT GCC GTT TAT ATC TCT TTC CAT ATT GTA GCG CTC CAG 
GAG CTC G 3’ 
Protein expression and purification 
Modified pFastBac vectors encoding various mutant forms of PLC-γ1 described 
above were transformed into DH10Bac cells (Invitrogen) to produce bacmid DNA, which 
was subsequently used to generate baculovirus in Sf9 cells according to the 
manufacturer’s protocol (Invitrogen Bac-to-Bac manual).  High Five insect cells at a 
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density of 1.5 – 2.0 X 106 cells/ml were infected with baculovirus encoding individual 
PLC-γ1 constructs at an MOI of ~1.0 for 48 hrs at 27°C. 
Recombinant PLC-γ1 constructs expressed in pFBLIC2 vector were purified as 
follow.  Cells were harvested at 3000 rpm and resuspended in 150 ml of buffer NA (20 
mM Tris (pH 8), 300 mM NaCl, 10 mM imidazole, 10 % [v/v] glycerol) with 15 mM β-
mercaptoethanol (βMe) and four EDTA-free complete protease inhibitor tablets (Roche 
applied science).  Cells were lysed using an EmulsiFlex-C5 homogenizer (Avestin) and 
spun at 60,000 rpm for 1h at 4°C.  The clarified supernatant was loaded onto a 5 ml 
HisTrap FF crude column (GE Healthcare) charged with Ni2+.  Purification steps 
included a 15-column volume (CV) buffer NA wash and a 12 CV wash with 5% NB 
buffer (NA buffer containing 1 M imidazole).  Recombinant PLC-γ1 proteins were eluted 
with 7 CV of 40% NB buffer.  Eluted PLC-γ1 proteins were dialyzed overnight against 
buffer N2 (20 mM Tris (pH 8), 300 mM NaCl, 10% [v/v] glycerol) in the presence of the 
TEV protease and 2 mM DTT to remove the His6 tag from the PLC-γ1 proteins.  Cleaved 
proteins were then subjected to a second passage over a Ni2+ charged metal chelate 
column.  Fractions containing purified proteins were diluted in QA buffer (20 mM Tris 
(pH 8), 50 mM NaCl, 10% [v/v] glycerol, 2 mM DTT), subsequently loaded onto a 1 ml 
SourceQ anion exchange column (GE Healthcare), and eluted in a linear gradient of 0% - 
50% buffer QB (QA + 1 M NaCl) over 20 CV.  Fractions containing purified PLC-γ1 
proteins were then loaded onto a HiLoad 16/70 Superdex200 column (GE Healthcare) to 
ensure samples eluted as monodisperse species of correct molecular weight.  Purified 
PLC-γ1 proteins were pooled and concentrated using a 30K MWCO Vivaspin 20 
centrifugal filtering device (Vivascience).  Protein concentrations were determined using 
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Beer’s law with extinction coefficients calculated using the ProtParam tool (ExPaSy 
Molecular Biology Server (265)), analyzed by SDS-PAGE to confirm concentration and 
ensure purity, and subsequently stored at -80°C after flash freezing in liquid nitrogen. 
PLC-γ1 recombinant proteins expressing a non-cleavable His6 tag (pFBLIC 
vector) were purified as described above with minor modifications.  Proteins were eluted 
from the first metal affinity column and dialyzed for four hours against buffer N2 and 
overnight against buffer QA.  The proteins were then applied to a 1 ml SourceQ column, 
and the rest of the purification scheme followed the above description. 
Recombinant isolated PLC-γ1 domains (nSH2, cSH2, X/Y-linker, and split PH) 
expressed in p15LIC2 vector were expressed in BL21 (DE3) Escherichia coli strain.  
Cells were grown at 37°C in LB medium containing 0.1 mg/ml ampicillin until an A600 of 
~0.7 was attained, and then were induced with 50 µM isopropyl β-D-
thiogalactopyranoside (IPTG) and grown at 18°C for 16 – 18 h.  The nSH2, X/Y-linker, 
and split PH domains were purified by sequential metal affinity chromatography, TEV 
protease treatment overnight, followed by a second metal affinity column and a size-
exclusion chromatography using a HiLoad Superdex75 16/70 column (GE Healthcare). 
The cSH2 domain purification included an additional cation-exchange chromatography 
step using a MonoS column (GE Healthcare) between the second affinity column and the 
gel filtration column.  All proteins were concentrated using a 5K MWCO Vivaspin 20, 
flash-frozen in liquid nitrogen, and stored at -80°C. 
The FGFR2K E565A construct expressed in p15LIC2 vector was expressed in the 
BL21 (DE3) Escherichia coli strain.  To improve protein expression and solubility, cells 
were grown in TB medium supplemented with 0.1 mg/ml ampicillin until an A600 of ~3.0, 
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then induced with 50 µM IPTG and grown at 18°C for 16 – 18 h.  The purification 
scheme followed that of the nSH2 and split PH domains of PLC-γ1 described above. 
PLC-γ1 recombinant proteins expressed in pPICZ-LIC vector were expressed according 
to the manufacturer’s protocol (Invitrogen, EasySelect Pichia Expression Kit) with minor 
modifications.  The PLC-γ1 constructs were linearized using PmeI and then transformed 
into SMD1163H using electroporation.  Pure clonal transformants were selected, tested, 
and optimized for effective PLC-γ1 protein expression.  Recombinant PLC-γ1 proteins 
were purified as described above. 
Measurement of PLC-γ  activity in mammalian cells 
The accumulation of [3H]inositol phosphates was measured in transiently 
transfected HEK293 or HEK293T cells as previously described (64).  Western blotting 
was performed to confirm the expression of each PLC construct in HEK cells using a 
monoclonal antibody directed toward the HA epitope (Covance).  β-actin (Sigma) 
antibody was used as a loading control. 
In vitro reconstitution assays to measure [3H]PtdIns(4,5)P2 hydrolysis 
Two different procedures were utilized for measuring phospholipase activity of 
PLC enzymes.  Initial experiments measuring maximum enzymatic activity were carried 
out in the presence of a detergent substrate mixture.  The second assay employed 
phospholipid vesicles. 
Maximum enzymatic activity was determined for wild-type PLC-γ1 and PLC-
γ1ΔX/Y-linker as previously described (64, 215) with minor modifications.  Briefly, lipid 
vesicles containing 500 µM liver phosphatidylethanolamine (PE), 50 µM brain 
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PtdIns(4,5)P2, and ~10,000 cpm/assay [3H]PtdIns(4,5)P2 (PerkinElmer) were created by 
combining the lipids, drying the mixture under a stream of nitrogen, and resuspending the 
dried lipid mixture in 20 mM HEPES (pH 7.4), using a probe sonicator.  PLC-γ1 proteins 
were incubated in final buffer conditions including 20 mM HEPES, pH 7.4, 70 mM KCl, 
3 mM EGTA, 2 mM dithiothreitol (DTT), 0.16 mg/ml fatty acid-free bovine serum 
albumin (FAF-BSA), 0.5% sodium cholate, and 10 µM free Ca2+.  Incubations were 
initiated by the addition of PLC-γ1 and terminated after 10 min at 32°C.  Reactions were 
stopped by addition of 200 µl of 10% (v/v) trichloroacetic acid (TCA) and 100 µl of 10 
mg/ml FAF-BSA to precipitate uncleaved lipids and protein.  Centrifugation of the 
reaction mixture isolated soluble [3H]Ins(1,4,5)P3, which was quantified by liquid 
scintillation counting. 
Most experiments to determine enzymatic characteristics and potential regulation 
by FGFR2K utilized phospholipid vesicles containing 25 µM brain PtdIns(4,5)P2, 500 
µM brain PE, and ~10,000 cpm/assay [3H]PtdIns(4,5)P2.  The lipid vesicles were created 
as described above.  Final buffer conditions were 20 mM HEPES (pH 7.4), 70 mM KCl, 
3 mM EGTA, 2 mM DTT, 0.16 mg/ml FAF-BSA, and 10 µM free Ca2+ in a final volume 
of 60 µl.  All reactions were performed at 30°C for 10 min after the addition of the 
indicated PLC-γ1 mutant form.  Reactions were terminated as described above and 
[3H]Ins(1,4,5)P3 was quantified by liquid scintillation counting of the soluble fraction 
after centrifugation of the reaction mixture. 
For both methods, serial dilution of PLC-γ1 proteins was performed using a 10x dilution 
buffer containing 200 mM HEPES (pH 7.4), 500 mM NaCl, 20 mM DTT, and 10 mg/ml 
FAF-BSA. 
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In vitro kinase assay 
Equimolar concentrations (35 µM) of FGFR2K E565A and PLC-γ1 were 
incubated in a buffer containing 20 mM HEPES (pH 7.4), 50 mM NaCl, 50 µM ATP, 10 
mM MnCl2, 0.2 mM Na3VO4, 2 mM DTT, 50 ng/ml FAF-BSA, and 1 µl of [γ-32P]ATP 
(10 mCi/ml; PerkinElmer) on ice in a final volume of 70 µl.  After one hour, 10 µl was 
removed and used in the phospholipase assay described above.  Another 10 µl was 
subjected to SDS-PAGE analysis followed by Coomassie brilliant blue staining.  After 
extensive destaining, bands corresponding to PLC-γ1 proteins were excised, washed with 
acetonitrile solvent, and dried using a speed vac.  Recovery of radioactivity from gel 
pieces was determined by Cherenkov counting. 
Isothermal titration calorimetry 
ITC studies were carried out on a VP-ITC (MicroCal, GE Healthcare) at 25°C.  In 
general, macromolecules were dialyzed in 50 mM HEPES, pH 7.5, and 50 mM NaCl and 
peptides were dissolved in the same buffer prior to use. Peptides (450 µM to 1 mM) or 
split PH domain (1 mM) were titrated into macromolecules [Isolated SH2 domains (35 to 
50 µM) or X/Y-linker (45 to 70 µM)] in a 1.45 ml sample cell.  Titrations were 
performed while samples were stirred at 300 rpm.  An initial 2 µl injection was followed 
by 30 injections of 10 µl each with a 4-min delay between injections to allow for signal to 
return to baseline.  The data were fit with a single independent site binding model using 
Origin software (MicroCal).  Background reaction enthalpy due to titrant dilution or 
buffer dilution of macromolecule was determined from the last 5 – 10 injections, and data 
were corrected for background heat released prior to curve fitting. 
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Concentrations of both protein and phosphopetide were determined using the A280 
and A267 respectively and the extinction coefficients, calculated using ProtParam for the 
protein, and of Tyr (1050 M-1 cm-1) and phospho-Tyr (652 M-1 cm-1) for the 
phosphopeptides.  Peptides were synthesized at the Tufts Core Facility, Boston, MA.  
The PLC-γ1-derived peptides had the following sequence: acetyl-
DYGALYEGRNPGFYEAN-amide and the FGFR2K-derived peptide acetyl-
TNEEYLDLSQ-amine, with the phosphorylated tyrosine underlined. 
Size-exclusion chromatography – multi angle light scattering (SEC-MALS) 
Light scattering measurements were made with a Wyatt DAWN EOS light 
scattering instrument (Wyatt Optilab refractometer, and Wyatt dynamic light scattering 
module) coupled to an AKTA FPLC (GE Healthcare).  A Superdex200 10/300 GL (GE 
Healthcare) pre-equilibrated with 20 mM Tris (pH 8.0), and 200 mM NaCl was loaded 
with 250 µl of PLC-γ1 proteins at ~ 4.0 mg/ml.  Data collection and analysis were 
performed with ASTRA software version 4.90.08 (Wyatt technologies). 
Circular dichroism 
Purified isolated X/Y-linker proteins, either wild-type or Δ10, at a concentration 
of 0.125 mg/ml in 20 mM sodium phosphate buffer (pH 7.5), were analyzed by circular 
dichroism at 25°C using a Chirascan circular dichroism spectrophotometer 
(AppliedPhotophysics) with a 10 mm pathlength.  Data were plotted as mean residue 
ellipticity as a function of wavelength. 
RESULTS 
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Purified PLC-γ1 is monomeric and inhibited by its X/Y-linker 
Full-length rat PLC-γ1, purified to homogeneity after heterologous expression in 
insect cells, was predominantly monomeric with a minor aggregate component based on 
its light scattering properties after elution from a size exclusion column (Figure 16A).  
The majority of the C-terminal region following the C2 domain is degenerate in PLC-γ 
isozymes, and aggregation was eliminated with PLC-γ1 lacking its last 71 amino acids 
(residues 1 – 1219; Figure 15A).  Consequently, unless otherwise noted, all work 
described here with purified PLC-γ1 used this truncated form.  The molecular weights for 
both monomeric species of purified PLC-γ1 measured using size exclusion 
chromatography coupled to multi-angle light scattering (SEC-MALS) were within 2 
kilodaltons of their calculated molecular weights based on amino acid composition 
(Figures 15A and 16A) and were consistent with their elution volumes from size 
exclusion columns calibrated with molecular weight standards (data not shown).  
Similarly, the specific activities of both forms of purified PLC-γ1 determined with 50 µM 
[3H]PtdIns(4,5)P2 were ~1 pmol/min/ng (Figure 15B and data not shown), consistent with 
specific activities reported for endogenous (45) and recombinant (289) PLC-γ1.  As 
discussed below, it was necessary to use the yeast, Pichia pastoris, for expression of 
certain very active mutants of PLC-γ1. Therefore, we also compared the properties of 
wild-type PLC-γ1 purified after expression in yeast (Pichia pastoris) versus insect cells 
(Trichoplusia ni).  The two samples of purified PLC-γ1 exhibited identical specific 
activities, molecular weights, and hydrodynamic radii measured by SEC-MALS (Figure 
16B), indicating that the intrinsic physical properties of PLC-γ1 are independent of 
expression system. 
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We recently showed that deletion of the entire X/Y-linker of PLC-δ1 or -ε 
increased basal phospholipase activity 10-100 fold in transfected cells (64).  Deletion of 
portions of the X/Y-linker of PLC-β2 increased basal phospholipase activity 10-100-fold 
in cells, and the specific activity of purified PLC-β2 lacking twenty residues of its X/Y-
linker was 10-fold greater than PLC-β2 with an intact X/Y-linker (64).  Given these 
observations, we examined potential auto-inhibitory roles for the elaborated X/Y-linker 
within PLC-γ isozymes.  Thus, PLC-γ1 lacking its entire X/Y-linker (residues 471 – 938; 
PLC-γ1ΔX/Y-linker) was purified to homogeneity after expression in Pichia pastoris.  
Pichia was utilized for expression of this mutant since its expression in insect cells 
prevented baculovirus replication.  This is presumably due to highly elevated 
phospholipase activity since PLC-β2 lacking its X/Y-linker also cannot be made using 
baculovirus unless it is rendered catalytically inactive.  The specific activity of purified 
PLC-γ1ΔX/Y-linker (~180 pmol/min/ng) was ~150-fold greater than PLC-γ1 with an 
intact X/Y-linker (Figure 15B) indicating that PLC-γ1 is dramatically auto-inhibited by 
its X/Y-linker.  It is unclear why a previous study reported only modest (4-fold) 
enhancement of phospholipase activity for a mutant of PLC-γ1 that roughly corresponds 
to PLC-γ1ΔX/Y-linker (242).  
A minimal inhibitory motif of PLC-γ1 maps to the BG loop of the C-terminal SH2 
domain   
A series of deletions were introduced to delimit the minimal auto-inhibitory 
portion of the X/Y-linker of PLC-γ1, and the activities of these mutants were determined 
after transient expression in HEK293 cells (Figure 17A).  Removal of the entire X/Y-
linker, the SH-array, or the C-terminal SH2 (cSH2) domain produced robust constitutive 
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activation of PLC-γ1.  In contrast, removal of the split PH (sPH) domain modestly 
elevated phospholipase activity; and loss of either the nSH2 domain or the SH3 domain 
did not substantially affect phospholipase activity.  These results suggest that the cSH2 
domain within the X/Y-linker of PLC-γ1 is the main determinant mediating auto-
inhibition of phospholipase activity.   
The mutant forms of PLC-γ1 did not express to identical levels (Figure 17A).  In 
particular, PLC-γ1ΔX/Y-linker was poorly expressed over the range of concentrations (50 
– 150 ng) of transfected expression vectors tested.  To more accurately compare the 
phospholipase activities of PLC-γ1ΔX/Y-linker and PLC-γ1ΔcSH2, the corresponding 
expression vectors were transfected at lower concentrations (Figure 18A).  The 
expression levels of the two PLC-γ1 mutants were more comparable under these 
conditions, and the corresponding phospholipase assays indicate that PLC-γ1ΔX/Y-linker 
and PLC-γ1ΔcSH2 are both similarly active (within a factor of 2), further substantiating 
the idea that the cSH2 domain of PLC-γ1 is the main determinant for auto-inhibition of 
phospholipase activity. 
The series of PLC-γ1 mutants harboring deletions within the X/Y-linker 
subsequently were purified to homogeneity and tested for phospholipase activity (Figure 
18B).  Consistent with the previous transfection experiments, deletion of the cSH2 
domain, but not the nSH2 domain or the SH3 domain, substantially (~50-fold) elevated 
the phospholipase activity of PLC-γ1.  Surprisingly, the phospholipase activity of purified 
PLC-γ1ΔsPH was essentially equivalent to the phospholipase activity of purified PLC-
γ1ΔcSH2 despite the fact that PLC-γ1ΔsPH exhibited only modest increases in basal 
phospholipase activity after transient expression in HEK293 cells.  These results suggest 
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that the sPH domain might stabilize the auto-inhibitory conformation of the cSH2 domain 
and that this stabilization is more pronounced within a cellular milieu.  However, we 
were unable to detect an interaction between the purified sPH and cSH2 domains using 
isothermal titration calorimetry (ITC) (Figure 18C) suggesting that any potential 
stabilization of the auto-inhibited state of PLC-γ1 involves, at best, weak direct 
interactions between the two domains.   
The cSH2 domain of PLC-γ1 was subjected to more extensive mutagenesis to 
define potential regions responsible for auto-inhibition of phospholipase activity (Figure 
17B).  The recent crystal structure of the tandem SH2 domain of PLC-γ1 bound to the 
kinase domain of fibroblast growth factor receptor 1 (FGFR1) highlights a set of loops 
within the nSH2 domain that, in addition to the canonical phosphate-binding pocket, are 
needed for engagement of FGFR1 (169).  Reasoning that the equivalent loops in the 
cSH2 domain might participate in intramolecular interactions needed for auto-inhibition, 
we introduced a series of single substitutions into specific loops (BC, DE, EF) of the 
cSH2 domain of PLC-γ1, and the mutant isozymes were tested for altered phospholipase 
activity in HEK293 cells.  In all cases, the mutants of PLC-γ1 isozymes exhibited 
phospholipase activities indistinguishable from wild-type PLC-γ1 (data not shown).  
Two small deletions (Δ10 and Δ30) were subsequently introduced into PLC-γ1 
near the end of the cSH2 domain (Figure 17B) and similarly tested (data not shown).  The 
Δ10 (residues 746 – 755) deletion results in removal of ten residues that encompass the 
highly mobile BG loop and the short βG strand not found in all SH2 domains; the Δ30 
(residues 759 – 788) deletion removes thirty residues encompassing Tyr783, which is 
critical for phosphorylation-mediated activation of PLC-γ1.  PLC-γ1Δ30 maintained 
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wild-type phospholipase activity indicating that Tyr783 most likely does not participate 
directly in auto-inhibition.  In contrast, the phospholipase activity of PLC-γ1Δ10 was 
roughly equivalent to PLC-γ1ΔcSH2 implicating the BG loop in mediating phospholipase 
auto-inhibition.   
To support these results, the two deletion mutants of PLC-γ1 were purified to 
homogeneity and their specific activities compared (Figure 17B).  Consistent with the 
cellular studies, the specific activities of purified PLC-γ1Δ10 and PLC-γ1ΔcSH2 were 
essentially equivalent, and enzyme activity was elevated approximately 40-fold relative 
to wild-type PLC-γ1.  In contrast, the specific activity of PLC-γ1Δ30 was 
indistinguishable from that of wild-type PLC-γ1.  Therefore, some portion of the cSH2 
domain encompassing the BG loop and subsequent βG strand is critical for auto-
inhibition of PLC-γ isozymes.  The trivial explanation that deletion of the BG loop and 
βG strand promotes unfolding of the cSH2 domain can be dismissed since the amount 
and type of secondary structure of the purified X/Y-linker of PLC-γ1 and the equivalent 
portion lacking these ten residues are essentially identical based on circular dichroism 
spectroscopy (Figure 18D).  Also, Tyr783 and the surrounding sequence, while essential 
for phosphorylation-induced activation of PLC-γ1, does not directly participate in auto-
inhibition since its deletion did not affect basal phospholipase activity.   
Mechanism of auto-inhibition is conserved in PLC-γ2 
PLC-γ1 and -γ2 possess identical domain architecture, 50% sequence identity, and 
77% sequence similarity.  Therefore, we hypothesized that PLC-γ1 and -γ2 are similarly 
auto-inhibited.  To test this idea explicitly, a series of deletions were individually 
introduced into the X/Y-linker of PLC-γ2, and the phospholipase activity of the resulting 
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mutant isozymes was determined after expression in HEK293T cells (Figure 19).  As 
expected based on the earlier studies with PLC-γ1, PLC-γ2ΔX/Y-linker exhibited robust 
lipase activity relative to wild-type PLC-γ2.  More informatively, however, PLC-γ2Δ10 
also had essentially the same high level of phospholipase activity as PLC-γ2ΔX/Y-linker, 
and thus, PLC-γ2, like PLC-γ1, is strongly auto-inhibited by a mechanism that requires 
the region encompassing the BG loop of the cSH2 domain.  PLC-γ2ΔYY harbors a 
deletion centered on Tyr759, which is analogous to Tyr783 in PLC-γ1 and is deleted in 
PLC-γ1Δ30.  Like PLC-γ1Δ30, PLC-γ2ΔYY exhibited low basal phospholipase activity, 
supporting the conclusion that this region, while required for activation upon its 
phosphorylation, does not directly participate in auto-inhibition.  The phospholipase 
activity of PLC-γ2ΔsPH and wild-type PLC-γ2 were essentially indistinguishable 
supporting the idea that the split PH domain is not critical for auto-inhibition of 
phospholipase activity.   
In total, these analyses indicated that PLC-γ1 and PLC-γ2 share identical modes 
of auto-inhibition that require a portion of the region encompassed by the BG loop and 
βG strand of the cSH2 domain.   
PLC-γ1 activity is dependent on Tyr783 phosphorylation 
Phosphorylation of Tyr775 or Tyr783 has been shown to be essential for 
activation of PLC-γ1 downstream of the B-cell receptor (BCR) (178) and RTKs (276); 
phosphorylation of the analogous tyrosines (753 and 759) in PLC-γ2 is also essential for 
its activation by tyrosine kinases (199, 286, 290, 291).  As shown above, deletion of 
residues that surround these tyrosines had no impact on auto-inhibition of lipase activity 
of either PLC-γ2 (ΔYY) or -γ1 (Δ30) (Figure 20A).  To begin to place phosphorylation of 
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these tyrosines into a mechanistic framework for activation of auto-inhibited PLC-γ 
isozymes, Tyr775 and Tyr783 of PLC-γ1 were substituted for phenylalanine, either 
individually or in combination and the resulting mutant PLC-γ1 isozymes were purified 
to homogeneity.  Phospholipase activity was quantified after phosphorylation of the 
purified mutants with the constitutively active kinase domain of fibroblast growth factor 
receptor 2 (FGFR2K) (Figure 20B), a RTK known to phosphorylate and activate PLC-γ1 
(165).  Approximately 4 moles of phosphate were incorporated into purified wild-type 
PLC-γ1 under these conditions, and phospholipase activity was accelerated 
approximately 10-fold.  Mutation of Tyr775 did not substantively affect the level of 
FGFR2K-promoted phosphorylation or phospholipase activity indicating that 
phosphorylation of Tyr775 is not essential to relieve auto-inhibition.  In contrast, 
mutation of Tyr783, either alone or in combination with Y775F, reduced FGFR2K-
promoted phosphorylation of PLC-γ1 and completely abrogated kinase-stimulated 
enhancement of phospholipase activity.  Thus, phosphorylation of Tyr783 is crucial for 
relief of auto-inhibition.  Phosphorylation of Tyr771 also was suggested to regulate lipase 
activity of PLC-γ1 (276).  However, this tyrosine is not conserved in PLC-γ2 (Figure 
21A), and its mutation affected neither the degree of FGFR2K-promoted phosphorylation 
nor the lipase activity of purified PLC-γ1 (Figure 21B).   
Tyrosine phosphorylation often regulates protein function by introducing highly 
localized negative charge that can be mimicked by substitution of the phosphorylated 
tyrosines with glutamic acid.  However, this is not the case for PLC-γ1, since tandem 
substitution of Tyr775 and Tyr783 with glutamic acid failed to increase the 
phospholipase activity of PLC-γ1 (Figure 20C).   
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Interaction between phosphorylated Tyr783 and the C-terminal SH2 domain is 
required for phosphorylation-mediated activation of PLC-γ1  
A previous report suggested that phosphorylated Tyr783 of PLC-γ1 directly 
interacts with its cSH2 domain and that this association is required for enhanced 
phospholipase activity of partially purified PLC-γ1 (272).  Aspects of this idea were 
tested directly using purified proteins (Figure 22).  A peptide encompassing 
phosphorylated Tyr783 of PLC-γ1 bound with high affinity (KD ~0.4 µM) to the purified 
cSH2 domain of PLC-γ1 (Figure 22A) as measured by ITC.  The phosphorylated peptide 
showed a clear preference for the cSH2 domain of PLC-γ1 (Figure 22B) since the affinity 
of complex formation was ~8-fold lower (KD ~2.5 µM) if the peptide was titrated with 
purified nSH2 domain under identical conditions.  Conversely, the nSH2 domain of PLC-
γ1 preferentially bound (KD ~0.4 µM) a relevant phosphorylated peptide of FGFR2 as 
opposed to the phosphorylated peptide of PLC-γ1 (Figure 22C).   
Phosphorylation of Tyr783 was required for association since the equivalent non-
phosphorylated peptide exhibited no affinity for purified cSH2 domain under identical 
conditions (Figure 22D).  The equivalent peptide phosphorylated on Tyr775 (Figure 22E) 
also bound to the cSH2 domain, but with an affinity (KD ~1.8 µM) 4-5-fold lower than 
observed with the peptide phosphorylated at Tyr783.   
The isolated cSH2 domain of PLC-γ1 has the capacity to bind dually 
phosphorylated peptides as highlighted in the crystal structure of this domain bound to a 
dually phosphorylated peptide from the Syk tyrosine kinase (273).  While it is uncertain 
whether Syk engages PLC-γ1 in this manner under physiological conditions, a peptide of 
PLC-γ1 dually phosphorylated on Tyr775 and Tyr783 bound to the purified cSH2 domain 
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of PLC-γ1 with an affinity (KD ~0.7 µM) intermediate between the singly phosphorylated 
forms of the peptide (Figure 22F). 
The results from these titration experiments are consistent with occurrence of an 
intramolecular association with the cSH2 domain of PLC-γ1 driven by tyrosine 
phosphorylation.  This idea was directly tested using purified forms of PLC-γ1 mutated in 
either the N- or C-terminal SH2 domain to prevent the binding of phosphorylated 
tyrosines (Figure 22G).  The constitutively active kinase domain of FGFR2 enhanced the 
phospholipase activity of PLC-γ1 harboring a defective nSH2 domain (nSH2*) by 
approximately 10-fold, which is similar to the rate enhancement shown earlier for wild-
type PLC-γ1.  In contrast, PLC-γ1 with a defective cSH2 domain (cSH2*) was refractory 
to stimulation by the kinase domain of FGFR2.  These results are consistent with the idea 
that phosphorylation of Tyr775 or Tyr783 prompts intramolecular association of this 
phosphorylated region with the cSH2 domain and that this association is required for 
enhanced phospholipase activity.   
The peptide of PLC-γ1 containing phosphorylated Tyr783 bound to purified X/Y-
linker of PLC-γ1 with an affinity (KD ~3.5 µM) approximately 10-fold lower than 
observed in equivalent titrations with the cSH2 domain  (Figure 23A).  This result 
suggests that the interface within the cSH2 domain needed for engagement of the 
phosphorylated peptide is at least partially occluded within the larger X/Y-linker.  This 
conclusion is supported by the fact that it was not possible to use ITC to measure the 
affinity of the X/Y-linker of PLC-γ1 for the corresponding peptide phosphorylated on 
Tyr775 (Figure 23B).   
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Substantial conformational rearrangement of PLC-γ1 is linked to phospholipase 
activation 
Poulin et al. (272) previously suggested that engagement of the cSH2 domain of 
PLC-γ1 by phosphorylated Tyr783 leads to a conformational rearrangement within PLC-
γ1, but this proposal was based solely on differential retention of phosphorylated forms of 
PLC-γ1 during chromatography with a heparin matrix.  To directly examine this concept, 
we applied SEC-MALS to measure potential conformational changes in PLC-γ1 upon its 
activation.   
Phosphorylation of PLC-γ1 in vitro likely would produce a heterogeneous 
preparation containing isozyme with differing amounts and sites of phosphorylation that 
would confound biophysical analyses.  Consequently, purified PLC-γ1Δ10 was assumed 
to recapitulate potential conformational changes within phosphorylated and activated 
PLC-γ1, and therefore, was studied as a reasonable surrogate (Figure 24).  As shown 
earlier (Figure 15 and 16), PLC-γ1 was monodisperse with an experimentally measured 
molecular weight equal to its calculated molecular weight.  Similarly, the experimentally 
measured molecular weights of PLC-γ1 and PLC-γ1Δ10 were also identical (Figure 24B) 
as expected for two proteins differing by less than 0.1% of total mass.  In contrast, the 
hydrodynamic radius of PLC-γ1Δ10 was approximately 6.5% larger than the equivalent 
value for PLC-γ1 (4.9 versus 4.6 nm) indicating that constitutively active PLC-γ1Δ10 
exists in a substantively different conformation than auto-inhibited PLC-γ1.   
Interestingly, the intact and Δ10 versions of the X/Y-linker of PLC-γ1 retain 
identical hydrodynamic radii (and molecular weights) (Figure 25) suggesting that the 
conformational rearrangement in PLC-γ1Δ10 relative to PLC-γ1 does not reflect gross 
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rearrangement within the X/Y-linker itself.  Rather, the alteration of conformation derives 
from changes in the spatial rearrangement of the X/Y-linker relative to the remainder of 
the protein.  This result is also consistent with the previous circular dichroism studies 
indicating no change in the overall secondary structure of the X/Y-linker upon 
introduction of Δ10 (Figure 18D).  PLC-γ1Δ15 lacks fifteen residues adjacent to the 
deletion found in PLC-γ1Δ10 (Figure 24A).  However, PLC-γ1Δ15 remains auto-
inhibited and its hydrodynamic radius was unchanged relative to PLC-γ1 (Figure 24C).  
Overall, these data strongly argue that the regulated phospholipase activity of PLC-γ1 is 
tightly linked to a substantial conformational rearrangement of PLC-γ1 with a transition 
from a “closed” basally inhibited state to an “open” activated state.   
DISCUSSION 
Model for the activation of PLC-γ  isozymes 
We have shown that the phospholipase activity of PLC-γ isozymes is repressed 
primarily by the cSH2 domain located within the highly elaborated X/Y-linker of these 
enzymes.  Moreover, specific deletion of ten residues encompassing the highly mobile 
BG loop of the cSH2 domain is sufficient to activate PLC-γ isozymes to the same extent 
as removal of the entire X/Y-linker (Figures 17 and 19).  In contrast, the other domains 
within the X/Y-linker are ancillary to auto-inhibition of phospholipase activity (Figure 
17A).  Activation is associated with an increase in the hydrodynamic radius of the full-
length protein that cannot be recapitulated by introduction of an identical deletion into the 
isolated X/Y-linker (Figure 24B and 25).  In a similar vein, the capacity of the cSH2 
domain to bind phospho-tyrosine peptides must be maintained to relieve this auto-
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inhibition (Figure 22G), and phosphomimetic substitution of the physiologically relevant 
tyrosines within PLC-γ1 is insufficient to drive activation (Figure 20C). 
A simple model that fits these data posits a compact and basally inhibited state of 
PLC-γ isozymes mediated by the cSH2 domain directly engaging the phospholipase 
active site to block entrance of PtdIns(4,5)P2 substrate (Figure 26).  PLC-γ isozymes are 
recruited to membranes through docking of the nSH2 domain to a phospho-tyrosine-
containing region of a RTK or cytoplasmic tyrosine kinase, but simple recruitment is 
insufficient to release auto-inhibition and promote phospholipase activity.  Instead, 
activation is coupled to phosphorylation, by the docked kinase, of specific tyrosines 
within the PLC-γ isozyme (e.g., Tyr783) that engage the cSH2 domain to disrupt its 
interactions with the catalytic TIM barrel and concomitantly free the active site for entry 
of substrate.  Disruption of interactions between the cSH2 domain and active site is 
associated with a large conformation change within the full-length PLC-γ isozyme that 
most likely reflects an alteration in the spatial disposition of the entire X/Y-linker with 
respect to the remainder of the enzyme.   
The small GTPase, Rac2, directly binds the split PH domain of PLC-γ2 to 
enhance its phospholipase activity, and this activation does not require tyrosine 
phosphorylation of PLC-γ2 (191, 193, 194).  While deletion of the split PH domain of 
PLC-γ2 did not enhance its phospholipase activity in cells (Figure 19), the equivalent 
deletion modestly activated PLC-γ1 in cells (Figure 17A), and this effect was more 
pronounced with purified PLC-γ1 (Figure 17B).  Thus, the split PH domain is not 
essential for auto-inhibition of PLC-γ isozymes, but apparently buttresses the position of 
the cSH2 domain for auto-inhibition.  If true, Rac2 likely promotes activation of PLC-γ2 
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by influencing the position of the cSH2 domain through its interactions with the split PH 
domain.   
The SHP phosphatases possess tandem SH2 domains that share substantial 
sequence homology (30% identity) with the equivalent portion of the PLC-γ isozymes.  
Indeed, detailed structural analysis of the SHP phosphatases (274, 275) highlight striking 
similarities to the model proposed here for the regulation of PLC-γ isozymes.  The nSH2 
domain of SHP phosphatases blocks the active site leading to repression of phosphatase 
activity.  Engagement of this domain by phospho-tyrosine-containing regions within 
substrates and docking proteins causes structural changes within the nSH2 domain that 
concomitantly destabilizes interactions with the active site to elevate phosphatase activity 
up to 10-fold (276).  The two SH2 domains can simultaneously engage the same target 
substrate through separate phospho-tyrosine-containing regions, in which case 
phosphatase activity is elevated greater than 100-fold (276).  Therefore, the tandem SH2 
domains of PLC-γ isozymes and SHP phosphatases perform dual functions: i) they 
repress intrinsic catalytic activity and ii) they integrate phosphorylation of specific 
tyrosines to the relief of auto-inhibition leading to high catalytic activity that is 
preferentially localized in the vicinity of substrates.   
Critical role of the cSH2 domain 
The interface of the nSH2 domain of SHP-2 with its phosphatase domain is 
centered on the DE and FB loops of the SH2 domain (274).  However, targeting the 
equivalent loops within the cSH2 domain of PLC-γ1 failed to identify sites critical for 
auto-inhibition of phospholipase activity indicating that the two SH2 domains do not 
share identical determinants necessary for auto-inhibition.   
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In contrast, we identified the BG loop of the cSH2 domain as a critical 
determinant for regulated auto-inhibition of PLC-γ isozymes (Figures 17 and 19).  
Similar to many SH2 domains, the BG loop of the cSH2 domain of PLC-γ1 forms part of 
the groove needed to bind phospho-tyrosine-containing peptides (277).  Perhaps not 
surprisingly then, the BG loop of the cSH2 domain of PLC-γ1 alters its conformation 
upon peptide engagement and different peptides stabilize distinct conformations of the 
BG loop (293, 298, 299).  An attractive possibility is that changes in the conformation of 
the BG loop in response to binding phospho-tyrosine-containing peptides are key to the 
release of auto-inhibition.  In the simplest form of this scenario, the BG loop directly 
engages the catalytic TIM barrel to occlude the active site, and this occlusion is 
destabilized upon peptide engagement by the cSH2 domain.  This idea is supported by 
the fact that removal of the BG loop induces a large conformational change within full-
length PLC-γ1 that results in full constitutive activation of the phospholipase (Figures 17 
and 24).  This conformational change is not observed if the BG loop is deleted within the 
context of the isolated X/Y-linker suggesting that conformational alterations upon 
activation of full-length PLC-γ1 arise due to en bloc movement of the X/Y-linker relative 
to the remainder of the enzyme (Figure 22).  This model does not preclude the possibility 
that other portions of the cSH2 domain participate in interactions with the TIM barrel to 
contribute to auto-inhibition. 
Homma et al. showed that fragments corresponding to the SH array of PLC-γ1 
could inhibit several PLC isoforms (-β1, -δ1, -γ1 and -γ2) and that this inhibition was 
non-competitive using PLC-γ1 (278).  Further studies delimited a series of short peptides 
that required the BG loop for inhibition of PLC-γ1 in vitro and in vivo (278).  These 
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results were interpreted to suggest that the peptides directly interacted with the active site 
of the PLC isozymes.  Our results are consistent with the possibility of the BG loop 
directly engaging the active site of PLC-γ isozymes, but it is difficult to envision how 
peptides of the BG loop of PLC-γ1 could inhibit multiple PLC isoforms unless the site of 
interaction is highly conserved among all PLCs.   
Differential phosphorylation 
The differential roles of tyrosines 775 and 783 of PLC-γ1 in regulating 
phosphorylation-induced activation is superficially perplexing.  That is, multiple lines of 
evidence indicate that both tyrosines (178), or the equivalent sites (753 and 759) in PLC-
γ2 (199, 286, 290, 291), can be functionally redundant in phosphorylation-dependent 
activation of PLC-γ isozymes.  Indeed, peptides of PLC-γ1 phosphorylated at either site 
bound to the isolated cSH2 domain of PLC-γ1, albeit with a five-fold difference in 
affinity (Figure 22).  However, when the kinase domain of FGFR2 was used to 
phosphorylate PLC-γ1, substitution of Tyr783, but not Tyr775, resulted in a PLC-γ1 
mutant refractory to activation (Figure 20B).  One possible explanation for these results is 
that physiologically relevant kinases exhibit differential capacity to phosphorylate 
Tyr775 and Tyr783 in PLC-γ1.  Indeed, Tyr775 of PLC-γ1, or its equivalent in PLC-γ2 
(Tyr753), has been implicated in regulating PLC-γ isozymes downstream of immune 
receptor signaling controlled by cytosolic tyrosine kinases.  To the best of our 
knowledge, neither Tyr775 of PLC-γ1 nor Tyr753 of PLC-γ2 has been shown to be 
necessary for activation downstream of RTKs, including FGFR2.   
The possibility that multiple tyrosines within a PLC-γ isozyme fulfill important 
physiological functions should not be entirely dismissed.  That is, we illustrated that a 
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peptide from PLC-γ1 phosphorylated at both Tyr775 and Tyr783 bound essentially as 
well to the cSH2 domain of PLC-γ1 as the equivalent peptide phosphorylated at Tyr783 
alone (Figure 22), and this dual phosphorylation might be expected to have substantial 
regulatory ramifications.  For example, a dually phosphorylated peptide of Syk bound to 
the cSH2 domain of PLC-γ1 elicited large changes in the BG loop of the cSH2 domain 
(273) in comparisons to this domain alone or the domain bound to a singly 
phosphorylated peptide of PDGF (298, 299).  These results suggest that dual tyrosine 
phosphorylation might elicit differential levels of phospholipase activation due to 
differential structural responses.  Alternatively, the SH2 domain of the adapter protein, 
APS, binds dually phosphorylated regions of certain kinases to sustain signaling through 
enhanced protection to dephosphorylation (279).  Similar alterations in PLC-γ activity 
might also depend on the sites and number of phosphorylations within the X/Y-linker.   
Core regulation 
We previously proposed a general model for regulated auto-inhibition of PLC 
isozymes by their X/Y-linkers (64).  The X/Y-linker of most PLCs is highly negatively 
charged and mainly disordered with no predicted domains.  Nonetheless, these mobile 
X/Y-linker are auto-inhibitory since their deletion in several PLC families (-δ, -β, -ε) 
leads to constitutive phospholipase activity easily reaching 100-fold over basal levels 
(64).  Based on structural constraints, these mobile X/Y-linkers must reside in the vicinity 
of the phospholipase active site so that auto-inhibition arises due to a combination of 
steric occlusion and electrostatic repulsion from negatively charged membranes.  
Consequently, any input, i.e., binding to a membrane-resident protein or 
phosphoinositide, that preferentially recruits a PLC and orients its active site toward the 
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membrane should force the X/Y-linker away from the active site and enhance 
phospholipase activity.  This parsimonious model accounts for the diverse set of 
upstream inputs capable of activating PLCs with primarily disordered and negatively-
charged X/Y-linkers.   
The PLC-γ isozymes, with their highly elaborated X/Y-linkers consisting of 
multiple domains, suggest a fundamentally different regulation.  This perception is 
reinforced with the knowledge that PLC-γ isozymes are activated upon phosphorylation 
of specific tyrosines within their X/Y-linkers.  Nevertheless, these structural and 
regulatory differences between the PLC-γ isozymes and the remainder of the family 
potentially obscure core regulation preserved within the entire PLC family.  Indeed, it 
appears that the X/Y-linker is a major regulatory module in all PLCs, and the PLC-γ 
isozymes evolved elaborate X/Y-linkers to preserve basal auto-inhibition while coupling 
phospholipase activation to tyrosine phosphorylation mediated by RTKs and cytoplasmic 
tyrosine kinases.  
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Figure 15: Purified PLC-γ1 is monomeric and auto-inhibited by its X/Y-linker.   
(A) Purified PLC-γ1 is monomeric.  Schematic representation of full-length rat PLC-γ1 
(upper panel).  PLC isozymes contain a conserved core consisting of: an N-terminal PH 
domain (cyan), an array of four EF hands (yellow), a catalytic TIM barrel composed of X 
and Y boxes (red), and a C-terminal C2 domain (green).  PLC-γ isozymes are unique in 
containing multiple domains within the X/Y-linker: a split PH domain (cyan), two SH2 
domains (navy and purple), and an SH3 domain (gold).  The C-terminus (dotted) of PLC-
γs is degenerate; unless otherwise noted, studies reported here used PLC-γ1 truncated at 
residue 1219.  Lower panel; elution of PLC-γ1 from a size exclusion column and 
monitored by absorbance (gray line) was simultaneously analyzed with multi-angle light 
scattering (black line) to provide a mean molecular weight of 141.6 kDa consistent with a 
monomer (calculated molecular weight of 140.1 kDa).  Purity of PLC-γ1 protein (2 µg, 
inset) was assessed by SDS-PAGE analysis followed by staining with Coomassie brilliant 
blue.   
(B) Removal of the X/Y-linker constitutively activates purified PLC-γ1.  Lipase activity 
of purified PLC-γ1 (left) or PLC-γ1ΔX/Y-linker (right) was measured at the indicated 
protein concentrations using mixed detergent-phospholipid micelles.  Indicated specific 
activities are the mean of at least three independent experiments.  Purity (2 µg, inset) of 
PLC-γ1 proteins was assessed by SDS-PAGE analysis followed by Coomassie brilliant 
blue staining. 
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Figure 16: Full-length PLC-γ1 exists in a monomer-dimer equilibrium in solution.   
(A) Full-length PLC-γ1 (1290 residues) is mainly monomeric with a small amount of 
dimer.  The mean molecular weight (<151.4 kDa>) of PLC-γ1 derived from the molar 
mass (black line) assessed by SEC-MALS as a function of the elution volume (gray 
curve; relative absorbance) of PLC-γ1 after application to a Superdex200 size exclusion 
column.  Calculated molecular weight of PLC-γ1 is 149.6 kDa; purity of PLC-γ1 (2 µg, 
inset) was assessed by SDS-PAGE followed by Coomassie brilliant blue; and schematic 
of domain architecture of PLC-γ1 provided above elution profile.   
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(B) PLC-γ1 purified from either yeast of insect cells has identical molecular weight, 
hydrodynamic radius, and specific activity.  In the upper panel, molar mass (left Y-axis; 
upper squares) and hydrodynamic radii (right Y-axis; lower squares) of PLC-γ1 purified 
from insect cells (blue color code) or yeast (red color code) assessed by SEC-MALS as a 
function of elution volume (light colored curves; relative absorbance) after application to 
a Superdex200 size exclusion column.  Mean (< >) molecular weights and hydrodynamic 
radii for eluted samples are identical at <141.5 kDa> and <4.6 nm>, respectively.  In the 
lower panel, lipase activity of PLC-γ1 purified either from insect cells (blue line) or yeast 
(red line) was measured at the indicated protein concentration using phospholipid 
vesicles. Purity (2 µg, inset) of PLC-γ1 was assessed by SDS-PAGE analysis followed by 
Coomassie brilliant blue staining. 
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Figure 17: Deletion mapping delineates a 10 residue span within the X/Y-linker of 
PLC-γ1 critical for auto-inhibition. 
(A) Systematic deletion of the domains in the X/Y-linker implicate the C-terminal SH2 
domain in mediating auto-inhibition.  HEK293 cells were transfected with the indicated 
amounts of DNA encoding either wild-type PLC-γ1 or the indicated deleted forms (left) 
prior to quantification of [3H]inositol phosphates (right).  Vector alone was subtracted 
from all measurements.  Data shown are the mean ± SD of triplicate samples and are 
representative of three or more independent experiments.  Western blotting (bottom) of 
cell lysates confirmed expression of PLC-γ1 deletion constructs. 
(B) High-resolution mutational mapping of the C-terminal SH2 domain highlights 10 
residues required for auto-inhibition.  Top bar chart plots percent identity per position of 
a multiple sequence alignment of 22 PLC-γ orthologs spanning the region deleted 
 113 
(residues 668 – 788) in rat PLC-γ1ΔcSH2.  Also shown on this chart are the secondary 
structure elements (purple) of the crystal structure of the cSH2 domain (PDB ENTRY 
entry 3GQI) with the nomenclature proposed by Harrison et al (280); two deletions (Δ10, 
red; Δ30, blue) introduced into PLCγ1; and Tyr783 required to be phosphorylated during 
receptor-mediated lipase activation.  Green bars highlight sites of substitution to alanine 
in PLC-γ1 yielding no change in [3H]inositol phosphate accumulation after transfection 
of mutant DNAs into HEK293 cell (data not shown).  In contrast, purified PLC-γ1 
proteins (bottom left) indicate that PLC-γ1ΔcSH2 and PLC-γ1Δ10 have comparable 
constitutive activation (bottom bar chart).  A subset of the multiple sequence alignment 
spanning Δ10 is shown at bottom right.  Specific activities are the mean ± SEM of at least 
three independent experiments using phospholipid vesicles and normalized to wild-type 
activity.  Purified proteins (2 µg; bottom left) assessed by SDS-PAGE followed by 
staining with Coomassie brilliant blue. 
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Figure 18: Auto-inhibition of PLC-γ1 is mediated by its C-terminal SH2 domain.   
(A) PLC-γ1ΔX/Y-linker and PLC-γ1ΔcSH2 have similar activities when expression 
levels are equalized.  HEK293T cells were transfected with the indicated amount of DNA 
encoding either PLC-γ1ΔX/Y-linker or PLC-γ1ΔcSH2 prior to quantification of 
[3H]inositol phosphates.  Vector alone was subtracted from all measurements.  Data 
shown are the mean ± SD of triplicate samples and are representative of data obtained in 
three or more independent experiments.  Western blotting of HEK293T cell lysates 
confirmed similar expression of PLC-γ1 deletion constructs. 
(B) The specific activities of purified wild-type PLC-γ1 and the indicated deletion forms 
of PLC-γ1 were measured in phospholipid vesicles containing [3H]PtdIns(4,5)P2.  Data 
are shown as specific activities ± SEM normalized to wild-type PLC-γ1 and are 
representative of at least three independent experiments.  Purity and equal concentration 
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(2 µg, inset) of PLC-γ1 proteins were assessed by SDS-PAGE analysis followed by 
Coomassie brilliant blue staining.  
(C) The isolated split PH domain of PLC-γ1 does not directly interact with the cSH2 
domain.  ITC curve for the interaction of the split PH domain with the cSH2 domain of 
PLC-γ1.  For this interaction, 10 µL injections (30 total) of the split PH domain were 
titrated into the sample cell containing the cSH2 domain at 25°C.  The top panel shows 
the baseline-corrected heats of titration; bottom panel shows the integrated heats released 
as a function of the molar ratio of split PH domain titrated into the cSH2 domain in the 
sample cell.  Data were corrected for the heat of dilution of the split PH domain and 
subsequently fit to a one-site model using the nonlinear least squares algorithm.  The 
extensive thermodynamic parameters obtained are given in Table 1. 
(D) Deletion of the BG loop does not affect the secondary structure of the X/Y-linker.  
Circular dichroism spectra of purified X/Y-linker (blue line) or X/Y-linkerΔ10 (red line) 
using a Chirascan circular dichroism spectrophotometer (AppliedPhotophysics).  Purity 
(2 µg, inset) of PLC-γ1 X/Y-linkers was assessed by SDS-PAGE analysis followed by 
Coomassie brilliant blue staining. 
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Figure 19: PLC-γ1 and -γ2 are auto-inhibited by analogous portions of the X/Y-
linker.   
HEK293T cells were transfected with the indicated amount of DNA encoding either 
wild-type PLC-γ2 or the deleted forms of PLC-γ2 (left) prior to quantification of 
[3H]inositol phosphates (right).  Vector alone was subtracted from all measurements.  
Data are the mean ± SD of triplicate samples and are representative of three or more 
independent experiments.  Western blotting of HEK293T cell lysates confirmed 
expression of PLC-γ2 constructs. 
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Figure 20: Phosphorylation, but not phosphomimetic mutation, of tyrosine 783 
enhances the lipase activity of purified PLC-γ1. 
(A) Expanded view of PLC-γ1 sequence between the C-terminal SH2 domain and SH3 
domain.  Tyrosines previously implicated in phosphorylation-dependent activation of the 
lipase are highlighted in red.  Also marked are deletions (Δ10, Δ30) described in Figure 
17.   
(B) Phosphorylation of tyrosine 783, but not 775, activates PLC-γ1.  Equimolar 
concentrations of purified PLC-γ1 or the indicated phospho-deficient forms were 
incubated with purified, constitutively active kinase domain of FGFR2 (FGFR2K) and [γ-
32P]ATP in BSA-containing buffer.  Aliquots of reaction mixtures were subsequently 
tested for: i) lipase activity in phospholipid vesicles (left Y-axis) and ii) incorporation of 
[γ-32P]phosphate into PLC-γ1 (right Y-axis) after SDS-PAGE followed by staining with 
Coomassie brilliant blue (lower gels).  Specific activities are the mean ± SEM of three or 
more independent experiments and normalized to basal activity of wild-type PLC-γ1. 
(C) Phosphomimetic mutations of tyrosine 775 and 783 are insufficient to enhance the 
lipase activity of PLC-γ1.  The specific activity of either purified PLC-γ1 or the doubly 
mutated (Y775E/Y783E) form was measured in mixed detergent-phospholipid micelles.  
Data are the mean ± SD of triplicate samples and are representative of three or more 
independent experiments.  Purity (2 µg, inset) of PLC-γ1 proteins was assessed by SDS-
PAGE followed by staining with Coomassie brilliant blue. 
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Figure 21: Equivalent of tyrosine 783 of PLC-γ1 is invariant among PLC-γ  
isozymes.   
(A) Multiple sequence alignment of the regulatory region spanning residues 755 – 793 in 
rat PLC-γ1 was generated from 22 different PLC-γ orthologs using ClustalX. The percent 
conservation for each residue is depicted in pink as a bar graph below the alignment. 
(B) Phosphorylation of tyrosine 771 of PLC-γ1 is not necessary for enhanced lipase 
activity.  Equimolar concentrations of the indicated phospho-deficient forms of PLC-γ1 
were incubated with purified, constitutively active kinase domain of FGFR2 (FGFR2K) 
and [γ-32P]ATP in BSA-containing buffer.  Aliquots of reaction mixtures were 
subsequently tested for: i) lipase activity in phospholipid vesicles (grey bars) and ii) 
incorporation of [γ-32P]phosphate into PLC-γ1 (black squares) after SDS-PAGE followed 
by staining with Coomassie brilliant blue (lower gels).  Specific activities are the mean ± 
SEM of three or more independent experiments and normalized to basal activity of wild-
type PLC-γ1. 
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Figure 22: Phosphorylated tyrosine 783 must interact with the C-terminal SH2 
domain for activation of purified PLC-γ1.   
(A – F) Phosphorylation of Tyr783 mediates high-affinity interaction with the C-terminal 
SH2 domain of PLC-γ1.  Heats evolved from titration of individual SH2 domains of 
PLC-γ1 (nSH2 or cSH2) with indicated peptides of PLC-γ1 or FGFRK2 were measured 
with isothermal titration calorimetry and used to derived associated dissociation constants 
(KD).  The range of residues are indicated for the peptides as well as phosphorylated 
(circled red P) and non-phosphorylated tyrosines (Y).  Top panels show the baseline-
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corrected heats of titration; bottom panels show the integrated heats released as a function 
of the molar ratio of peptide titrated into the sample cell.  Data were corrected for the heat 
of dilution of the peptide and subsequently fit to a one-site model using a nonlinear least 
squares algorithm to obtain the associated KD values.  Measured thermodynamic 
parameters are given in Table 1.   
(G) Mutations within the phospho-tyrosine binding pocket of the C-terminal SH2 domain 
of PLC-γ1 prevent receptor-mediated lipase activation.  PLC-γ1 was mutated to prevent 
binding of phospho-tyrosine to either the N-terminal (nSH2*) or C-terminal (cSH2*) 
SH2 domain, purified and incubated with an equimolar concentration of purified 
FGFR2K and [γ-32P]ATP.  Aliquots of the reaction mixtures were subsequently 
quantified for: i) lipase activity using phospholipid vesicles (left Y-axis), and ii) 
incorporation of [γ-32P]phosphate in PLC-γ1 (right Y-axis) after SDS-PAGE and staining 
with Coomassie brilliant blue (lower gels).  Specific activities are the mean ± SEM for 
three or more independent experiments and are normalized to wild-type activity. 
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Figure 23: Phospho-tyrosine binding pockets are occluded in the X/Y-linker.   
Heats evolved from titration of X/Y-linker of PLC-γ1 with indicated peptides of PLC-γ1 
measured with ITC were used to derive dissociation constants (KD).  Top panels show the 
baseline-corrected heats of titration; bottom panels show the integrated heats released as a 
function of the molar ratio of peptide titrated into the sample cell.  Data were corrected 
for the heat of dilution of the peptide and subsequently fit to a one-site model using a 
nonlinear least squares algorithm to obtain the associated KD values.  Measured 
thermodynamic parameters are given in Table 1. 
 122 
 
Figure 24: PLC-γ1 adopts an extended conformation upon activation. 
(A) Specific activity of either purified PLC-γ1 or the indicated deleted forms was 
measured in phospholipid vesicles.  Relative specific activities are the mean ± SEM for 
three or more independent experiments and are normalized to wild-type activity.  Note 
that data for PLC-γ1 and PLC-γ1Δ10 are repeated from Figure 17 and shown here for 
comparative purposes.   
(B-C) SEC-MALS analysis of either PLC-γ1Δ10 (B) or PLC-γ1Δ15 (C) compared to 
wild-type PLC-γ1.  Molar mass (left panels; dark colored squares) and hydrodynamic 
radius (right panels; dark colored squares) of the indicated proteins were assessed by 
multi-angle light scattering as a function of elution volume (light colored curves; relative 
absorbance) after application to a Superdex200 size exclusion column. Mean (< >) 
molecular weights and hydrodynamic radii for elutions are color-coded to the indicated 
proteins.  Note: In panel C, PLC-γ1Δ15 was generated within the context of full-length 
PLC-γ1 (1290 residues) and therefore compared to it. 
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Figure 25: Deletion of the BG loop does not induce gross conformational changes 
within the X/Y-linker. 
Wild-type (blue) and Δ10 (red) versions of the PLC-γ1 X/Y-linker have identical 
molecular weights and hydrodynamic radii.  Molar mass (left panel; blue and red colored 
squares) and hydrodynamic radius (right panel; blue and red colored squares) of indicated 
proteins assessed by multi-angle light scattering as a function of elution volume (blue and 
red curves; relative absorbance) after application to a Superdex200 size exclusion 
column. Mean (< >) molecular weights and hydrodynamic radii for elutions color-coded 
to the indicated proteins are provided. 
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Figure 26: Mechanism for phosphorylation-stimulated increase in PLC-γ1 lipase 
activity. 
In absence of stimulus, the catalytic domain (grey donut) of PLC-γ1 is basally auto-
inhibited by the cSH2 domain (purple cylinder).  Activation of RTKs (gold) provides 
phospho-tyrosine (red dot) docking site for the nSH2 domain (blue cylinder) of PLC-γ1, 
thereby translocating PLC-γ1 from the cytosol to the plasma membrane.  RTKs then 
phosphorylate PLC-γ1 at specific tyrosine, which promotes direct interactions with the 
cSH2 domain.  Engagement of the cSH2 domain by phosphorylated tyrosine induces 
structural rearrangements of the cSH2 domain with respect to the catalytic domain, 
leading to release of auto-inhibition, and subsequent substrate hydrolysis 
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Table 1. Summary of isothermal titration calorimetry measurements. 
 
Syringec 
Sample 
celld 
Na,b KDb (µM) 
ΔHb 
(kcal/mol) 
TΔSb 
(kcal/mol) 
pY783 cSH2 1.01 ± 0.12 0.36 ± 0.06 −13.8 ± 0.5 −5.04 ± 0.6 
pY783 nSH2 0.93 ± 0.02 2.50 ± 0.67 −4.6 ± 1.7 3.08 ± 1.5 
pY769 nSH2 0.97 ± 0.08 0.40 ± 0.23 −2.4 ± 0.9 6.4 ± 0.5 
YY cSH2 N/A - - - 
pY775 cSH2 1.01 ± 0.03 1.8 ± 0.25 −8.0 ± 0.3 −0.19 ± 0.3 
pY775 
pY783 
cSH2 1.02 ± 0.12 0.67 ± 0.05 −16.7 ± 0.08 −8.3 ± 0.04 
pY783 X/Y-linker 2.03 ± 0.01 3.05 ± 1.3 -9.84 ± 0.8 -2.3 ± 0.5 
pY775 X/Y-linker N/A - - - 
splitPH cSH2 N/A - - - 
 
a = stoichiometry 
b = standard deviation derived from 2-3 independent experiments 
c = peptides and macromolecules in the injection syringe with concentration 
     ranging from 450 µM to 1 mM 
d = macromolecules in the ITC sample cell with concentration ranging from 35 µM 
      to 70 µM 
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CHAPTER 4:  CONCLUSIONS AND FUTURE DIRECTIONS 
CONCLUSIONS 
Although PLC enzymes are critical in regulating phosphoinositide and calcium 
levels, their activation mechanisms remain elusive.  A recent study proposed a general 
mechanism for the regulated auto-inhibition of PLC-β, -δ, and -ε isozymes by their 
highly electronegative X/Y-linkers (64).  In this model, activators of these PLC isoforms 
serve as anchor points to the plasma membrane to optimally orient and facilitate 
electrostatic repulsion between the X/Y-linker and the proximal acidic phospholipids.  
Release of auto-inhibition is not driven by conformational changes induced by 
engagement of the different activators, but rather by electrostatic and steric forces 
between their mostly disordered X/Y-linkers and the inner leaflet of the plasma 
membrane (64). 
PLC-γ isozymes are structurally distinct from other PLC isoforms in having 
acquired modular domains – a split PH domain, two SH2 domains, and an SH3 domain – 
within their X/Y-linker.  In addition to the unique structural nature of the X/Y-linker, the 
activation of PLC-γ isozymes is directly associated with its phosphorylation status.  In 
this work, we defined the mechanism of phosphorylation-mediated activation of PLC-γ 
isozymes. 
We established the C-terminal SH2 (cSH2) domain, within the X/Y-linker, as the 
critical structural determinant in regulating the activity of PLC-γ isozymes.  We 
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demonstrated that occupancy of the cSH2 domain defines the enzymatic state of PLC-γ 
isozymes.  In the absence of extracellular stimuli, the cSH2 domain is unbound and 
basally represses the phospholipase activity of PLC-γ isozymes to keep PLC-γ isozymes 
in the “closed”, inactive state.  After receptor activation, phosphorylation at a specific 
tyrosine, Tyr783 in PLC-γ1 (and analogous Tyr759 in PLC-γ2), promotes high affinity 
interactions with the cSH2 domain, which are required for phosphorylation-stimulated 
PLC-γ isozyme activity.  Occupancy of the cSH2 domain by the phosphorylated tyrosine 
triggers a conformational rearrangement of the X/Y-linker with respect to the catalytic 
domain to simultaneously release auto-inhibition and allow substrate access and 
subsequent hydrolysis, leading to an “open” activated state of PLC-γ isozymes.  
Together, our results demonstrated that PLC-γ isozymes have elaborated a common 
mechanism of auto-inhibition to couple tyrosine phosphorylation and displacement of a 
complex X/Y-linker. 
FUTURE DIRECTIONS 
Although our biochemical data allow us to propose a model for the regulated 
activation of PLC-γ isozymes, several questions remain unanswered.  How does the cSH2 
domain repress the basal activity of PLC-γ isozymes?  It is tempting to speculate that 
direct interactions take place between the cSH2 domain and the catalytic TIM barrel.  
However, high-resolution structural data for the auto-inhibited form of PLC-γ isozymes is 
needed to provide irrevocable answers.  As described in chapter two, several attempts 
have been made to crystallize the auto-inhibited form of PLC-γ isozymes.  However, in 
light of our biochemical analyses, the minimal functional unit within the X/Y-linker 
contains the cSH2 domain and the downstream region spanning the phosphorylated 
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tyrosine.  Therefore a construct encompassing the core structural domains (PH, EF, TIM, 
and C2 domains) in addition to the minimal functional unit should recapitulate the 
inhibitory state of PLC-γ isozymes and therefore serve as a new potential crystallographic 
target. 
Several additional crystallization approaches should be used to crystallize the 
different constructs of PLC-γ isozymes presented in chapter two.  Specifically, reductive 
methylation of solvent-exposed lysines changes the physical properties of the protein (pI, 
solubility, hydropathy index) and may promote crystal formation through improving 
crystal packing (281).  Another simple method that does not require further protein 
manipulation is the addition of small molecules to induce crystallography (282).  These 
additives may stabilize a protein conformation, or alter interactions with the solvent to 
induce positive associations between the solvent and the protein, or establish noncovalent 
crosslinks in crystals, and thereby promote crystal lattice formation (282).  One 
promising additive is the soluble head group of the substrate for PLC-γ isozymes, 
Ins(1,4,5)P3, which has been used previously in complex with the core domains of PLC-
δ1 (62).  Seeding may also trigger crystallization.  The seed solution can be made up of 
crushed crystals from either the same protein but different species or isozymes, or a 
closely related protein, is added to the supersaturated crystallization trial (283, 284).  For 
PLC-γ isozymes, crystals of apo-PLC-β2 could serve as seed solutions, as apo-PLC-β2 
contains the core structural domains shared by all PLC isoforms (64).  Thus, multiple 
techniques may allow crystallization of the auto-inhibited form of PLC-γ isozymes. 
The roles of the other domains within the X/Y-linker in regulating the activity of 
PLC-γ isozymes are another important question.  The split PH domain is the effector site 
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for Rac GTPases-mediated activation of PLC-γ2 (191, 194). The N-terminal SH2 (nSH2) 
domain is the interaction site for the phosphorylated tails of activated RTKs (169).  
Although the endogenous ligand for the SH3 domain of PLC-γ isozymes remains to be 
clearly identified, several studies report different potential binding partners for the SH3 
domain, such as the T-cell adaptor protein SLP-76 (307), the RhoGEF βPix (285), or the 
E3 ligase Cbl (286, 287).  Our results do not propose a functional role for these domains 
in regulating the activity of PLC-γ isozymes; however, they are likely to play an 
important role in proper cellular localization (nSH2 domain), down-regulation (SH3 
domain) of PLC-γ isozymes, and in providing structural support and integrity to the 
overall X/Y-linker.  It will be interesting to dissect the role of the split PH domain in 
PLC-γ1, as no activator equivalent to the Rac GTPase has been identified for PLC-γ1.  It 
is clear, however, that the split PH domain of PLC-γ isozymes does not mediate 
interactions with phospholipid, as it lacks the lipid-binding motif located between the 
strands β1 and β2 (288). 
Evolutionary analysis of the X/Y-linker of PLC-γ isozymes could be used as an 
alternative approach to crystallography to dissect the function of each modular domain or 
unit composing the X/Y-linker.  Indeed, it would be helpful to perform a thorough 
evolutionary analysis to identify the primordial unit of the X/Y-linker, the relationships 
between newly acquired domains, and the appearance of novel regulatory proteins.  It 
would be also informative to determine if the primordial unit of the X/Y-linker of PLC-γ 
isozymes was duplicated in other proteins, such that their regulatory mechanism is 
similar to the one presented for PLC-γ isozymes.  
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Our results illustrated that Tyr783 in PLC-γ1, or the analogous Tyr759 in PLC-γ2, 
is the preferred substrate for growth factor RTKs and that phosphorylation at Tyr783 is 
required for phosphorylation-stimulated PLC-γ1 activity (198, 276).  In contrast, 
activation of PLC-γ isozymes downstream of immune receptor signaling requires 
phosphorylation at either Tyr775 or Tyr783 in PLC-γ1 (178) or the equivalent, Tyr753 or 
Tyr759, respectively, in PLC-γ2 (199, 286, 290), suggesting that both tyrosines are 
functionally redundant in these systems.  It would be highly valuable to investigate the 
substrate specificity of the cytosolic kinases from Src, Syk, or Tec-family kinases in 
phosphorylating and subsequently activating PLC-γ isozymes. 
Our studies focused on understanding the phosphorylation-dependent mechanisms 
of PLC-γ isozymes activation.  Recent evidence indicates that alternative mechanisms to 
enhance the phospholipase activity of PLC-γ isoforms exist.  Indeed, Rac GTPases 
directly activate PLC-γ2 in a phosphorylation-independent mechanism (193).  Rac 
GTPases engage the split PH domain of PLC-γ2, within the X/Y-linker, to enhance the 
enzymatic activity of PLC-γ2 (191, 194).  While structural details of the complex 
between Rac and full-length PLC-γ2 would provide the resolution necessary to propose a 
mechanism for phosphorylation-independent activation of PLC-γ2, we speculate that 
engagement of the split PH domain by the small GTPase Rac induces a conformational 
change within the X/Y-linker of PLC-γ2 to release auto-inhibition and subsequently 
increase PLC-γ2 activity. 
With the biochemical tools now available to selectively activate PLC-γ isozymes 
through a chosen upstream activator, it is possible to directly assess the physiological 
effects of PLC-γ isozymes in a specific signaling pathway.  Indeed, we have identified a 
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small deletion within the cSH2 domain (Δ10) that bypasses the requirements for tyrosine 
phosphorylation to increase the activity of PLC-γ isozymes and therefore could be used in 
cellular assays to probe the effects of PLC-γ isozymes on cell growth and motility.  
Previous studies indicated a critical role of PLC-γ isozymes in EGFR-promoted cell 
transformation (201, 289).  Constitutively active forms of PLC-γ isozymes could be used 
in growth transformation assays, such as anchorage-independent growth (soft agar colony 
formation) (290), to assess the transforming potential of PLC-γ isozymes.  We predict 
that PLC-γ isozymes are oncogenes, as hyper-activity of PLC-γ isozymes will lead to 
tumor formation. 
Additional goals of this study are to use the mechanistic knowledge we acquired 
through biochemical and structural data to manipulate the enzymatic activity of PLC-γ 
isozymes in living cells.  Currently, selective PLC inhibitors are lacking, as conflicting 
results are observed with the reported PLC inhibitor (U73122) (291) when used in 
reconstitution assays to directly measure the enzymatic activities of several PLC isoforms 
(Dr. Hicks, personal communication).  To identify selective small molecules that inhibit 
the activity of PLC-γ isozymes, we are screening synthetic and endogenous chemical 
libraries in collaboration with Dr. Qisheng Zhang’s laboratory.  Another avenue to 
manipulate the activity of PLC-γ isozymes is to add a photocleavable derivative to PLC-γ 
proteins and monitor the spacio-temporal dynamics of PLC-γ isozymes in living cells 
(292).  Using this approach, the photosensitive light oxygen voltage 2 (LOV2) domain 
from phototropin (293) would be swapped for the cSH2 domain of PLC-γ isozymes, such 
that inhibition and activation of PLC-γ isozymes is now controlled through cell 
illumination. 
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